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CHAPTER -I 
INTRODUCTION 
 
  Oral drug delivery is the simplest and easiest way of administering drugs. 
Because of the greater stability, smaller bulk, accurate dosage and easy production, 
solid oral dosages forms have many advantages over other types of oral dosage forms. 
Therefore, most of the new chemical entities (NCE) under development these days are 
intended to be used as a solid dosage form that originate an effective and reproducible 
in vivo plasma concentration after oral administration (Vinay kumar et al., 2012). 
New chemical entities do not reach the expectation and requirements because 
of their poor oral bioavailability due to lower dissolution rate which is the rate 
limiting step for hydrophobic drugs.  
A most important parameter that is useful for poorly soluble drugs is the dose: 
solubility ratio of the drug. The dose: solubility ratio can be defined as the volume of 
gastrointestinal fluids necessary to dissolve the administered dose. When this volume 
exceeds the volume of fluids available, one may anticipate incomplete bioavailability 
from solid oral dosage forms. The aqueous solubility for poorly water-soluble drugs is 
usually less than 100 μg/ml (Vijaykumar Nagabandi et al., 2011).  
Increasing the dissolution and bioavailability of poorly soluble drugs is a 
major challenge facing the pharmaceutical industry today as about 40% of potential 
drugs produced are almost insoluble. As a general rule increase in dissolution done by 
increase in its solubility profile, this in turn end up in increased absorption (Gandhi, et 
al., 2013 and Kamalakanan V. et al., 2012). 
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Various techniques have been employed to formulate oral drug delivery 
system that would enhance the dissolution profile and in turn, the absorption 
efficiency of water insoluble drug such as micronization, adsorption onto high surface 
area carriers, lyophilization, co-grinding, formulation of inclusion complexes, 
solubilization by surfactants, solid dispersions, solid solutions, hydrotrophy, inclusion 
of the drug solution or liquid drug into soft gelatin capsules, and co solvency.  
BCS classification is a scientific framework which deals in classification of 
drug substances based on its aqueous solubility and intestinal permeability. 
Table 1: Biopharmaceutical Classification System 
(Brahmankar et al., 2009) 
Class Solubility Permeability 
I High High 
II Low High 
III High Low 
IV Low Low 
 
Among the four classifications class II and class IV drugs are those belonging 
to lipophillic molecules which dissolve slowly, poorly, irregularly and so have serious 
challenges in delivery like incomplete release from the dosage form, Poor 
bioavailability, increased food effects and high inpatient variability (A.A. Elkordy et 
al., 2013 and Kamalakanan V. et al., 2012). 
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Development of Dosage Forms with Poorly Water Soluble Drugs  
Various methods used to increase the solubility of poorly water soluble drugs 
which are given below.  
Micronization  
The particle size reduction technique enhance the solubility and dissolution 
rate of poorly water soluble drugs due to the enormous surface that is generated.  
Solvent Deposition  
In this method, the poorly aqueous soluble drug such as nifedipine is dissolved 
in an organic solvent like alcohol and deposited on an inert, hydrophilic, solid matrix 
such as starch or microcrystalline cellulose evaporation of solvent.  
Use of soluble Prodrug  
Here the physico-chemical properties of the drug are improved by bio-
reversible chemical alteration. The most common prodrug strategy involves the 
incorporation of polar or ionizable moiety into the parent compound to improve 
aqueous solubility.  
Solid dispersion  
It involves dispersion of one or more active ingredients in an inert carrier or 
matrix at solid state. Melting (fusion) method, solvent evaporation method or melting 
evaporation methods can be employed for the preparation of the solid dispersions. 
The dissolution rate of the solid dispersion depends on the type of carriers used or the 
type of the matrix forming polymers used (A. B. Pathan et al., 2012). 
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Liquisolid technique 
The new developed technique by Spireas liquisolid system improves the 
dissolution properties of water insoluble or poorly soluble drugs. The liquisolid 
technique is a novel concept where a liquid may be transformed into a free flowing, 
readily compressible and apparently dry powder by simple physical blending with 
selected carrier and coating material. The liquid portion, which can be a liquid drug, a 
drug suspension or a drug solution in suitable non-volatile liquid vehicles, is 
incorporated into the porous carrier material. Once the carrier is saturated with liquid, 
a liquid layer is formed on the particle surface which is instantly adsorbed by the fine 
coating particles. Thus, an apparently dry, free flowing, and compressible powder is 
obtained. Among them, liquisolid compacts is one of the most promising and new 
techniques which promotes dissolution rate of water insoluble drugs.  
The term liquisolid compact refers to immediate release or sustained release 
tablets or capsules, combined with the inclusion of appropriate adjuvant required for 
tabletting or encapsulating. 
Need of Liquisolid System  
The oral route remains the preferred route of drug administration due to its 
convenience, good patient compliance and low medicine production costs. In order 
for a drug to be absorbed into the systemic circulation following oral administration, 
the drug must be dissolved in the gastric fluids. Thus, one of the major challenges to 
drug development today is poor solubility, as an estimated 40% of all newly 
developed drugs are poorly soluble or insoluble in water. In addition, up to 50% of 
orally administered drug compounds suffer from formulation problems related to their 
low solubility and high lipophilicity. Bioavailability of poorly water soluble 
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hydrophobic drugs (class II in biopharmaceutics classification system) is limited by 
their solubility and dissolution rate. The dissolution rate of these drugs can be 
improved by decreasing particle size, decreasing crystallinity, and/or increasing the 
surface area. Several studies have been carried out to increase the dissolution rate of 
drugs by decreasing the particle size, by creating nanoparticles and microparticles. 
However, the fine drug particles have high tendency to agglomerate due to vander 
Waals attraction or hydrophobicity, which both result in a decrease in surface area 
over time. Another way of increasing the dissolution rate is adsorption of the drug 
onto a high-surface area carrier. In this technique, the drug is dissolved in an organic 
solvent followed by soaking of the solution by a high-surface-area carrier such as 
silica. Here, agglomeration of the drug particles is prevented due to the binding of 
drug to the carrier. However, due to the presence of the residual solvent in the drug 
formulation, it is disadvantageous to use toxic solvents. To overcome the problem, the 
technique of “liquisolid compacts” is a new and promising approach towards 
dissolution enhancement.  
Liquisolid compacts possess acceptable flowability and compressibility 
properties. They are prepared by simple blending with selected powder excipients 
referred to as the carriers and the coating materials. Many grades of cellulose, starch, 
lactose, etc. can be used as carriers, whereas silicas of very fine particle size can be 
used as coating materials. In such systems, the drug existed in a molecular state of 
subdivision and systems were free flowing, on-adherent, dry looking powders. This 
technique was successfully applied for low dose water-insoluble drugs. Due to 
significantly increased wetting properties and surface area of drug available for 
dissolution, liquisolid compacts of water insoluble substances may be expected to 
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display enhanced drug release characteristics and, consequently, improved oral 
bioavailability. Since dissolution of a nonpolar drug is often the rate limiting step in 
gastrointestinal absorption, better bioavailability of an orally administered water-
insoluble drug is achieved when the drug is already in solution, thereby displaying 
enhanced dissolution rates. The technique of liquisolid compacts has been 
successfully employed to improve the in vitro release of poorly water soluble drugs 
such as Carbamazepine, Famotidine, Piroxicam, Indomethacin, Hydrocortisone, 
Naproxen and Prednisolone (A.B Pathan et al., 2012). 
Advantages 
 Huge number of Bio-Pharmaceutical classification class II drugs with high 
permeability, slightly or very slightly water soluble and practically insoluble 
liquids and solid drugs can be formulated into liquisolid systems. 
 Improvement of bioavailability of an orally administered water insoluble 
drugs is achieved. 
 This principle governs or administers the mechanism of drug delivery from 
liquisolid systems of powdered drug solutions and it is mainly responsible for 
the improved dissolution profiles exhibited by this preparations. 
 In this technique, production cost is low compared to soft gelatin capsules. 
 Drug is formulated in a tablet form or encapsulated dosage form and is held in 
solubilized liquid state, which confers developed or improved drug wetting 
properties thereby improving drug dissolution profiles. 
 Greater drug surface area is exposed to the dissolution medium. 
 This liquisolid system is specifically for powdered liquid medications. 
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 These liquisolid systems formulate into immediate release or sustained release 
dosage forms. 
 Optimized sustained release, liquisolid tablets or capsules of water insoluble 
drugs demonstrate constant dissolution rates (zero order release). 
 It is used in controlled drug delivery systems. 
 Drug can be molecularly dispersed in the formulation. 
 Drug release can be modified using suitable formulation ingredients. 
 Capability of industrial production is also possible. 
 Enhanced bioavailability can be obtained as compared to conventional tablets. 
 Differentiate the dosage form by admixture of colour into liquid vehicle. 
 To minimize excipients in formulation compare with other formulations like 
solid dispersions. 
 Omit the process approaches like nanonisation, micronization techniques 
(Syed et al., 2012 and Arya et al., 2011). 
Disadvantages 
 Formulation of high dose lipophilic drugs the liquisolid tablet is one of the 
limitations of this technique. 
 In order to achieve acceptable flowability and compactability for liquisolid 
powder formulation, high levels of carrier material and coating materials 
should be added. This will increase the weight of tablets to above one gram 
which makes them difficult to swallow. Consequently, it is impossible with 
conventional tablet methods to convert high dose to liquisolid tablets with a 
tablet weight of less than 50mg. Dissolution profile enhancement occurs in the 
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presence of low levels of hydrophilic carrier, where coating material is not 
significant (A. B. Pathan et al., 2012). 
Limitations 
 Not applicable for formulation of high dose insoluble drugs. 
 If more amount of carrier is added to produce free-flowing powder, the tablet 
weight increases to more than one gram which is difficult to swallow. 
 Acceptable compression properties may not be achieved since during 
compression liquid drug may be squeezed out of the liquisolid tablet resulting 
in tablets of unsatisfactory hardness. 
 Introduction of this method on industrial scale and to overcome the problems 
of mixing small quantities of viscous liquid solutions onto large amounts of 
carrier material may not be feasible (Sambasiva Rao. A et al., 2011). 
Principle of Liquisolid Compacts  
Important terminologies in Principle  
Liquid medication includes liquid lipophilic drugs and drug suspensions or 
solutions of solid water insoluble drugs in suitable non-volatile solvent systems.  
Liquisolid system refers to powdered forms of liquid medications formulated 
by converting liquid lipophilic drugs, or drug suspensions or solutions of water 
insoluble solid drugs in suitable non-volatile solvent systems, into dry, nonadherent, 
free-flowing and readily compressible powder admixtures by blending with selected 
carrier and coating materials.  
Carrier material refers to a preferably porous material possessing sufficient 
absorption properties, such as microcrystalline and amorphous cellulose, which 
contributes in liquid absorption.  
 CHAPTER
 
Liquisolid t
 
Coa
particles, su
particles an
Wit
flowing, re
with select
which can 
volatile liqu
et al., 2012
Iner
point such 
  I              
ablets of Pa
ting mate
ch as vario
d displayin
h the liqui
adily compr
ed excipien
be a liquid
id vehicles
) 
Figure 1
t, preferab
as propyle
                 
liperidone R
rial refers 
us types of
g a dry look
solid techn
essible and
ts named t
 drug, a d
, is incorpo
: Schemati
ly water-m
ne glycol, 
                 
eg. No. 261
to a materi
 silica, whi
ing powde
ology, a 
 apparently
he carrier a
rug suspen
rated into 
c represent
iscible org
liquid pol
                  
211302 
al possessi
ch contribu
r by adsorb
liquid may
 dry powde
nd coating
sion or a d
the porous 
ation of liqu
anic solven
yethylene g
                 
ng fine and
tes in cove
ing any exc
 be transf
r by simple
 material. T
rug solutio
carrier mate
isolid syste
t systems 
lycols, or 
INTRODU
 highly ad
ring the we
ess liquid. 
ormed into
 physical b
he liquid 
n in suitab
rial (Fig. 1
ms. 
with high 
glycerine 
CTION 
Page 9 
sorptive 
t carrier 
 
 a free 
lending 
portion, 
le non-
) (Baby 
boiling 
are best 
 CHAPTER  I                                                                                      INTRODUCTION 
 
Liquisolid tablets of Paliperidone Reg. No. 261211302  Page 10 
 
suitable as liquid vehicles. Once the carrier is saturated with liquid, a liquid layer is 
formed on the particle surface which is instantly adsorbed by the fine coating 
particles. Thus, an apparently dry, free flowing, and compressible powder is obtained. 
Usually, microcrystalline cellulose is used as carrier material and amorphous silicon 
dioxide (colloidal silica) as coating material. Various excipients such as lubricants and 
disintegrants may be added to the liquisolid system to produce liquisolid compacts 
(Fig. 2) (Syed et al., 2012) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Schematic outline of the steps involved in the preparation of 
liquisolid compacts. 
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Powdered drug solutions and suspensions may be produced from the 
conversion of drug solutions or drug suspensions into liquisolid systems and 
powdered liquid drugs are produced from the formulation of liquid drugs into 
liquisolid systems. 
B.  Based on the formulation technique used, liquisolid systems may be classified into 
two categories namely, 
1. Liquisolid compacts 
2. Liquisolid Microsystems 
The term “liquisolid compacts” refers to immediate or sustained release 
tablets or capsules prepared, combined with the inclusion of appropriate adjuvants 
required for tabletting or encapsulation, such as lubricants, and for rapid or sustained 
release action, such as disintegrants or binders, respectively. 
The term “liquisolid Microsystems” refers to capsules prepared by combining 
the drug with carrier and coating materials; combined with inclusion of an additive 
resulting in a unit size may be as much as five times that of liquisolid compacts 
(Sambasiva Rao et al., 2011 and Shashidher Burra et al., 2011). 
Mechanisms of enhanced drug release from liquisolid systems 
Several mechanisms of enhanced drug release have been postulated for 
liquisolid systems. The three main suggested mechanisms include an increased 
surface area of drug available for release, an increased aqueous solubility of the drug, 
and an improved wettability of the drug particles. Formation of a complex between 
the drug and excipients or any changes in crystallinity of the drug could be ruled out 
using DSC and XRD measurements. 
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a. Increased drug surface area 
If the drug within the liquisolid system is completely dissolved in the liquid 
vehicle it is located in the powder substrate still in a solubilized, molecularly 
dispersed state. Therefore, the surface area of drug available for release is much 
greater than that of drug particles within directly compressed tablets. 
          Accordingly, with increasing drug content exceeding the solubility limit and 
thus, increasing fraction of undissolved drug in the liquid vehicle the release rate 
decreases. With various drugs it could be shown that the release rates are directly 
proportional to the fraction of the molecularly dispersed drug (FM) in the liquid 
formulation. FM is defined by the ratio between the drug's solubility (Sd) in the liquid 
vehicle and the actual drug concentration (Cd) in this vehicle carried by each system. 
Therefore: 
F M= Sd /Cd 
Where  FM= 1 if  Sd ≥ Cd 
Accordingly, lower FM-values and higher fraction of undissolved drug in 
the liquid vehicle, respectively, are not sufficient to increase percentage of drug 
released at 30 min. However, this may not be transferred to other time points of drug 
release. 
b. Increased aqueous solubility of the drug 
In addition to the first mechanism of drug release enhancement it is expected 
that Cs, the solubility of the drug, might be increased with liquisolid systems. In fact, 
the relatively small amount of liquid vehicle in a liquisolid tablets is not sufficient to 
increase the overall solubility of the drug in the aqueous dissolution medium. 
However, at the solid/liquid interface between an individual liquisolid primary 
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particle and the release medium it is possible that in this microenvironment the 
amount of liquid vehicle diffusing out of a single liquisolid particle together with the 
drug molecules might be sufficient to increase the aqueous solubility of the drug if the 
liquid vehicle acts as a co-solvent. The overall increase in the solubility of drugs 
caused by liquisolid systems was confirmed. 
c. Improved wetting properties 
Due to the fact that the liquid vehicle can either act as surface active agent or 
has a low surface tension, wetting of the liquisolid primary particles is improved. 
Wettability of these systems has been demonstrated by measurement of contact angles 
and water rising times (Arya et al., 2011) 
Methodology  
Spireas et al proposed the new mathematical model in accordance to retain 
good flow behaviour and compressibility to design the formulation for Liquisolid 
technique. Mandatory requirements for this technique are suitable drug candidate, 
suitable non-volatile solvent, carrier and coating materials. According to Spireas et al 
the basic properties of Liquisolid powder for good flow behaviour and compressibility 
proposed are “Flowable liquid retention potential” (value) and compressible liquid 
retention potential” (ψ value), respectively.  
Flowable liquid retention potential defined as maximum weight of liquid 
(solvent) that can be retained per unit weight of powder (excipient) material to 
produce good flow. Compressible liquid retention potential defined as the 
compression force applied to produce tablets with acceptable strength without 
squeezing out any liquid during compression.  
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Excipient ratio (R) defined as Carrier to coating ratio as,  
R= Q/q 
Where, 
               Q= Carrier material 
                q= Coating material.  
Liquid load factor (Lf) defined as weight of liquid medicament (W) to weight of 
carrier (w).  
Lf = W/Q 
The Ø value is for calculating excipients quantities.  
Equation is,  
Lf = Ø + Ø (1/R) 
Where, Ø and Ø are values of carrier and coating material. 
Materials required for formulation 
Liquisolid system mainly includes 
 1. Drug candidate 
2. Non volatile solvent 
3. Disintegrant 
4. Carrier material 
5. Coating material 
1. Drug candidate 
These are poorly soluble or else insoluble drugs in water. 
2. Non volatile Solvent 
Non volatile Solvent should be inert, high boiling point, preferably water-
miscible and not highly viscous organic solvent systems and compatible with having 
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ability to solubilise the drug. The non volatile solvent acts as a binding agent in the 
liquisolid formulation. Various non-volatile solvents used for the formulation of 
liquisolid tablets includes 
1. Polyethylene glycol400 
2. Propylene glycol 
3. Polysorbate80 
4. Capryol 90 
Selection of Solvent 
To select the best non-volatile solvent for dissolving or suspending the drug in 
liquid medication, solubility studies of drug were carried out in different non-volatile 
liquid vehicles. Saturated solutions were prepared by adding excess drug to the liquid 
vehicles and it was shaked on the shaker for 48 hours at 25◦C under constant stirring. 
After this period the solutions were filtered through a 0.45 μm millipore filter, diluted 
with distilled water and analysed by UV-spectrophotometer at respected wavelength 
against blank sample (blank sample containing the same concentration of the specific 
solvent used without drug). Three determinations were carried out for each sample to 
calculate the solubility of drug. Some of the solvents mentioned can be incorporated 
to formulate Liquisolid tablets viz. Poly ethylene glycol (PEG 200, 400, 600), 
Propylene Glycol, Polysorbate 80, Glycerol, Spans, Polyoxyl 35 castor oil, capryol 90 
and poloxamer 181. The solvent should have the characteristic of a non-toxic and non 
volatile solvent. The formulation liquisolid compacts should neither enhance the 
dissolution rates nor retard the dissolution rates of the drug it depends upon the 
selection of solvent and properties of the chemical entities. Prior to selection of 
solvent selection in the formulation there is need to check the saturation solubility 
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with selected non-volatile solvents. From saturation solubility of solvent the one 
which has enhance rate of dissolution, the solvent with minimum solubility retards the 
rate of drug release 
3. Disintegrant 
Superdisintigrants increases the rate of drug release, water solubility and 
wettability of liquisolid granules. Mostly superdisintigrants like sodium starch 
glycolate, croscarmelose sodium, pre gelatinized starch and crosspovidone are used. 
4. Carrier Materials 
Carrier material should be porous material possessing sufficient absorption 
properties which contributes in liquid absorption. The carrier and coating materials 
can retain only certain amounts of liquid and at the same time maintain acceptable 
flow and compression properties hence, increasing moisture content of carrier’s 
results in decreased powder flowability. Various grades of microcrystalline cellulose 
such as avicel PH 102, avicel PH 200 and experimental grade of granular amorphous 
cellulose, lactose used as carrier materials. 
5. Coating Materials 
Coating material should be a material possessing fine and highly adsorptive 
particles which contributes in covering the wet carrier particles and displaying a dry-
looking powder by adsorbing any excess liquid. Coating material is required to cover 
the surface and maintain the powder flowability. Coating material includes silica 
(Cab-O-Sil) M5, Aerosil 200 (Rajesh K. et al., 2011). 
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Characterization of liquisolid tablets 
 Table 2: Characterization of liquisolid tablets (Sambasiva Rao et al., 2011) 
Characterization Purpose 
1. UV-spectrophotometer Assay & uniformity  content 
2. Infrared Spectroscopy Interaction studies 
3. Powder X-Ray Diffraction Analysis (XRD) Crystalline Properties 
4. Differential Scanning colorimetry (DSC) Interaction studies,  polymorphism 
5. In vitro Dissolution studies Release Properties of drug 
6. SEM analysis Surface morphology 
 
Importance of carrier and coating material ratio (R) 
Liquisolid systems pre-compression and drug release properties increase with 
powder excipient ratios (R) from 5:1 to 50:1. A linear relationship exists between the 
liquid load factors Lf and the reciprocal powder excipient ratios (1/R) required 
producing acceptable flowing and readily compressible liquid and powder admixtures. 
The linear relationship between Lf and the 1/ R plot of liquisolid systems possesses Y 
intercept and slope equal to the Φ values of the cellulose carrier powder and silica 
coating material. 
Liquisolid tablets dissolution rate profiles are affected by powder excipients 
ratio R in which results exhibited within the 5 minutes of the dissolution process 
against the r values 5 to 20 range R values. The dissolution rates increased almost 
proportionally to R until reaching an apparent maximum plateau at powder excipient 
ratios greater than 20. 
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Lower R values of liquisolid tablets contain relatively smaller amounts of 
carrier powder (cellulose), a large amount of fine coating particles (silica), and the 
ratios of their liquid medication per powder substrate are relatively higher. 
From the low liquid and powder ratios, a high presence of cellulose and low 
presence of silica may be directly associated with enhanced wicking, disintegration, 
and degradation properties. Low R values should justifiably display relatively poor 
dissolution profiles. After disintegration, low R values of liquisolid tablets are 
overloaded with liquid medication producing the primary particles. 
On other hand, in some cases, the drug diffusion through the primary particles 
may be rapid and might lead to overwhelming (solubility- wise) of the stagnant 
dissolution layers with drug. After maximum levels of dissolution are reached at 35 to 
45 R values, a slight gradual decrease of dissolution rate occurs with increasing 
powder excipient ratios. 
For R values higher than 50, they may be attributed to the slower diffusion of 
the liquid medication through the numerous porous carrier powder particles into 
which the drug solution has been embedded during the formulation process. To 
determine the effect of different type of carriers such as Avicel pH 102, lactose, starch 
or sorbitol, dissolve in solution containing 10% w/w of drug in liquid medication. 
Carriers show the potential to absorb the liquid medication. Large amounts of these 
carriers are necessary for regenerating liquid medication to dry looking and non 
adherent powder. 
Avicel PH 102 showed better results, due to its large specific area in 
comparison with other carriers such as lactose and starch. 
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Type of carrier might affect the unit size of liquisolid tablets. Higher Avicel 
PH 102 concentrations show uniform distribution of the drug by either adsorption 
onto or absorption into the carrier. Between the hydrogen groups, hydrogen bonds on 
adjacent cellulose molecules in Avicel PH 102 may account exclusively for the 
strength and cohesiveness of compacts. Avicel PH 102 compressibility and 
compactness characteristics can be explained by the nature if crystalline cellulosic 
particles themselves which are held together by hydrogen bonds which when 
compressed, are deformed plastically and a strong compact is formed due to the 
extremely excessive number of surfaces brought into contact during the plastic 
deformation, and the strength of the hydrogen bonds are formed. 
Non-volatile liquid vehicles such as propylene glycol, polyethylene glycol 
400, tween 80 and capryol 90 were shown to facilitate wetting of drug particles by 
decreasing interfacial tension between dissolution medium and the tablet surface. 
Increase in the wetting properties of liquisolid tablets by the dissolution media is one 
of the main reasons for the dissolution rate enhancement. High R values 30 to 60 
evidence better uniform distribution of the drug in the carrier material. (Shashidher 
Burra et al., 2011) 
Dissolution studies on liquisolid tablets 
Tablets should be sufficiently hard to resist breaking during normal handling 
and yet quickly disintegrate properly after swallowing. 
Dissolution rate (DR) is explained according to the “Noyes – Whitney” 
equation and “diffusion layer model” dissolution theories. 
DR = (D/h) S (Cs- C) 
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According to this equation, stagnant diffusion layer thickness is h, and formed 
by the dissolving liquid around the drug particles. D is the diffusion coefficient of the 
drug molecules transported through it, S is the surface area of the drug available for 
dissolution, C is the drug concentration in the bulk of the dissolving medium, and Cs 
is the saturation solution of the drug in the dissolution medium. Dissolution tests for 
liquisolid tablets were done at constant rotational speed and in identical dissolution 
media, thus allowing estimation of the thickness of the stagnant diffusion layer (h). 
From this equation, dissolution rate is directly proportional not only to the con-
centration gradient of the drug in the stagnant diffusion layer (Cs- C), but also to its 
surface area (S) available for dissolution. 
For estimation and comparison, drug dissolution rates (DR) of drug were used, 
with amount of drug dissolved per min presented by each tablet formulation during 
the first 10 minutes (Shashidher Burra et al., 2011).   
                                                          (M x D)  
                                             D R =    ––––––– 
                                                                    1000  
   
Where, 
           M = Total amount of pure drug in each tablet 
           D = Percentage of drug dissolved in the first 10 minutes 
Applications 
1. Rapid release rates are obtained in liquisolid formulations  
2. These can be efficiently used for water insoluble solid drugs or liquid lipophilic 
drugs.  
3. Sustained release of drugs which are water soluble drugs such as propranolol 
hydrochloride has been obtained by the use of this technique.  
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4. Solubility and dissolution enhancement.  
5. Designing of controlled release tablets.  
6. Application in probiotics. 
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CHAPTER-II 
LITERATURE REVIEW 
Ahmed S. Abdul Jabbar et al., 2013, formulated and evaluated piroxicam liquisolid 
compact different liquisolid compacts were prepared using a mathematical model to 
calculate the required quantities of powder and liquid ingredients to produce 
acceptably flowable and compressible admixture. The liquisolid formulation which 
might be attributed to the formation of hydrogen bonding between the drug and liquid 
vehicle this resulted in drug dissolution enhancement. 
Amal Ali Elkordy et al., 2013, studied spironolactone release from liquisolid 
formulations prepared with capryol 90, solutol HS-15 and kollicoat SR 30D as non-
volatile liquid vehicles were used in the design of spironolactone  liquisolid 
formulations, capryol 90, synperonic PE/L61 in combination with solutol HS-15 at a 
ratio of 1:1 and kollicoat SR 30D. Spironolactone liquisolid formulations were tested 
according to British Pharmacopoeia (BP) quality control tests. Liquisolid powder 
formulations formulated from a combination of synperonic PE/L61- solutol HS 
showed highest dissolution. The liquid vehicles used with spironolactone liquisolid 
formulations enhanced drug dissolution rate. 
Jarag Ravindra Jagannath et al., 2013, formulated and evaluated sustained release 
liquisolid tablets of metoprolol succinate. This is directed towards the development of 
liquisolid compact for the production of sustained release tablet of water soluble drug. 
Liquisolid compacts were prepared by using Tween 80 as the liquid vehicle or non-
volatile solvent. Avicel PH 102 as absorbing carrier and Aerosil 200 as adsorbing 
coating material. Tween 80 has plasticizer effect by which it can reduce the glass 
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transmission temperature of polymer and impart flexibility in sustaining the release of 
drug from liquisolid matrices. The results showed that wet granulation had a 
remarkable impact on the release rate of drug from liquisolid compacts reducing the 
release rate of drug from liquisolid compacts. 
 Gandhi K.J. et al., 2013, formulated, characterized and evaluated the liquisolid 
tablet containing pioglitazone HCl. The invitro release pattern of liquisolid tablets and 
directly compressed tablets were studied using USP-2 apparatus. The study concludes 
that the liquisolid technique is a promising alternative and best suitable method for 
enhancing solubility. 
Pandey A. et al., 2013, carried out project on dissolution rate enhancement of BCS 
Class II drug paliperidone by spray drying. The technique adopted is very well used 
industrially for preparing amorphous composition of poorly soluble crystalline drugs. 
In case of spray drying PAL with different classes of hydrophilic carriers (different 
grades of polyvinyl pyrolidones [PVPs, plasdones] and cellulosic polymers) were 
taken. Significant enhancement in dissolution rate was observed with the prepared 
spray dried compositions and out of three grades of plasdone; plasdone K12 
demonstrated the maximum enhancement in rate of release of PAL. Spray drying of 
PAL with plasdones, especially plasdone K12 reduced drug crystallinity, increased 
rate and extent of dissolution. 
 Pande V. V. et al., 2013, enhanced dissolution rate of rosuvastatin calcium by 
liquisolid compact technique. In this technique, liquid medications of water insoluble 
drugs in non-volatile liquid vehicles can be converted into acceptably flowing and 
compressible powders. As liquisolid compacts demonstrated significantly higher drug 
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release rate, they lead to a conclusion that it could be a promising strategy by 
improving the dissolution of poor water soluble drugs and immediate release solid 
dosage forms. 
Amal Ali Elkordy et al., 2012, performed liquisolid technique to enhance and sustain 
griseofulvin dissolution effect by using non-volatile liquid vehicles. They studied the 
effects of different liquid vehicles on release characteristics. Fast dissolution tablets 
were prepared using three different non-ionic surfactants namely cremophor EL, 
synperonic PE/L61 and capryol 90; on the contrary kollicoat SR 30P were used for 
production of sustained release formulations. Avicel PH102 and cab-O-sil M5 were 
used as a carrier and coating materials respectively. Cremophor EL showed the best 
dissolution enhancement with % PE of about 90% compared to only 23% of 
conventional tablets. 
Burra shashidher et al., 2012, formulated and evaluated carvedilol liquisolid tablets. 
A novel powder solution technology involves absorption and adsorption efficiency, 
which makes use of liquid medications, admixed with suitable carriers, coating 
materials and formulated into a free flowing, dry looking, non-adherent and 
compressible powder forms. The crystalline state of drug is changed to amorphous 
state due to liquisolid formation and is confirmed by both DSC and X-ray diffraction 
results. The amorphous form exhibited increased wetting properties because of 
subsequent increased surface area of the particle size. 
 Shah C.V.et al., 2012, designed, developed and optimized valsartan liquisolid tablets 
using Box – Behnken design. This study was designed to optimize and evaluate the 
effects of different formulation variables. Amount of liquid (X1),ratio of carrier to 
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coating material (X2) and amount of magnesium oxide (X3) on angle of repose (Y1), 
hardness (Y2) and invitro release (Y3) of formulation using three level Box –Behnken  
stastical design. The non–linear quadratic model generated by the design in the form 
of Y=A0 + A1X1 + A2X2 + A3X3 + A4X1X2 + A5X2X3 + A6X1X3 + A7X12 + A8X22 + 
A9X32 + E, where y is the measured response surface plots were depicted based on the 
equation given by the model. 
Dnyanesh walunj et al., 2012, formulated and evaluated tamoxifen citrate liquisolid 
compacts were prepared using a mathematical model to calculate the required 
quantities of powder and liquid ingredients to produce acceptably flowable and 
compressible admixture. Avicel PH 102, Aerosil 200, croscarmellose sodium and 
propylene glycol were employed as carrier, coating material, disintegrant and non-
volatile solvent respectively for preparing liquisolid compact. This study was 
concluded that liquisolid technique is a promising alternative for improvement of 
dissolution property of water insoluble drugs. 
Sateesh kumar Vemula et al., 2012, enhanced dissolution rate of nimesulide by 
liquisolid technique. Liquisolid tablets were prepared by using polyethylene glycol 
400 as a non-volatile liquid vehicle, microcrystalline cellulose, hydroxyl propyl 
methyl cellulose E-15, starch were used as carrier materials and silica gel as coating 
material in different ratios. Invitro dissolution profiles of liquisolid formulations were 
studied and compared with conventional formulation in pH7.4 phosphate buffer and it 
was found that liquisolid tablets formulated with microcrystalline cellulose showed 
significant higher drug release rates than conventional tablets due to increase in 
wetting properties. 
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Sidharth patil et al., 2012, formulated and evaluated liquisolid tablets of non 
steroidal anti inflammatory drug ibuprofen were prepared by using microcrystalline 
cellulose (Avicel PH 101) as a carrier material, silica gel as coating material, poly 
ethylene glycol 400 as non – volatile water miscible liquid vehicle and 5%sodium 
starch glycolate used as super disintegrating agent. The results showed that liquisolid 
formulations of ibuprofen exhibited higher percentage of drug release than marketed 
formulation. 
 Kamalakannan V. et al., 2012, formulated and evaluated tinidazole liquisolid 
tablets. A liquisolid system is formed by converting a liquisolid formulation into a 
dry, free-flowing and compressible powder mixture with selected carrier material and 
coating material. Liquisolid tablet formulation by using 20:1 ratio of powder 
excipients ratio (480mg of Avicel and 24mg of Cab-O-sil) and 100% w/w tinidazole 
in PG 600 solvent were satisfying the requirements. 
 Sirisha V.N.L. et al., 2012, prepared and evaluated (in vitro) liquisolid compacts of 
glibenclamide. Liquisolid tablets were prepared by using PEG 400 as non- volatile 
liquid vehicles and Avicel PH 101, Aerosil as carrier and coating materials 
respectively. The properties of glibenclamide particles were changed by dispersing 
the drug particles in a non–volatile liquid vehicle, which in turn increases the wetting 
properties and surface area of drug particles, and hence improve the dissolution 
profiles and oral bioavailability of the drug. 
Lakshmi P.K. et al., 2011, prepared and comparatively evaluated liquisolid compacts 
and solid dispersions of valsartan. Liquisolid technology and solid dispersion by 
kneading method used to improve the solubility of the drug by using non-volatile 
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solvents. Various non-volatile solvents were used such as PG, PEG and glycerin. The 
carrier and coating material play an important role in improving the solubility of the 
drug. Solid dispersion by kneading method is another attempt to improve solubility. 
Various carrier materials were used such as PVP K30, PEG 6000 and mannitol. These 
carriers were used in various ratios to improve its solubility. The results concluded 
that the liquisolid compacts enhanced the solubility of valsartan in comparison to 
traditional solid dispersion method. 
Vijayakumar Nagabandi et al., 2011, formulated, developed and evaluated 
liquisolid systems to improve the dissolution rate of ketoprofen using different carrier 
materials such as microcrystalline cellulose (Avicel PH101), starch, dicalcium 
phosphate, lactose and silica gel as coating material. Polyethylene glycol 400 was 
used as non-volatile water miscible liquid vehicle. The ratio of carrier to coating 
material was kept constant in all formulations of ketoprofen which exhibited higher 
percentage of drug release than marketed formulation.  
Vijayakumar Nagabandi et al., 2011, formulated, developed and evaluated 
liquisolid systems to improve the dissolution rate of naproxen with two different 
liquid vehicles, namely polyethylene glycol 400 and propylene glycol. Two different 
carrier materials were used namely microcrystalline cellulose (Avicel PH101) and 
dicalcium phosphate. Silica gel as coating material and sodium starch glycolate as 
disintegrating agent in all formulations. The results showed that liquisolid 
formulations of ketoprofen exhibited higher percentage of drug release than marketed 
formulation. 
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Ali Nokhodchi et al., 2010, studied the effect of co solvent and HPMC on 
theophylline release. Liquisolid tablets were prepared by mixing liquid medication 
with silica. Eudragit RL or RS followed by the compaction of the mixture. For 
comparison purposes physical mixtures of all ingredients were prepared. The effect of 
liquid medication and HPMC concentration on drug release was investigated. The 
sustained release action of HPMC was enhanced in liquisolid compacts in comparison 
to simple sustained release matrix tablets. 
Amal A. Elkordy et al., 2010, developed liquisolid systems to improve the 
dissolution rate of furosemide were prepared using microcrystalline cellulose (Avicel 
PH 101)as carrier and fumed silica (Cab-O-sil M-5) as coating material. Polyethylene-
polyoxypropylene-polyoxyethylene block copolymer (Synperonic PE/L81) 1, 2, 3 
propranolol, homopolymer, (a2) 9-octadecenoate (caprol PGE-860) and polyethylene 
glycol 400 (PEG 400) were used as non-volatile water miscible liquid vehicles. The 
results showed that all formulations exhibited higher percentage of drug dissolved in 
water (pH6.4-6.6) compared to that of acidic medium (pH1.2). Liquisolid compacts 
containing synperonic PE/L81 showed higher release rate at different pH values. 
Formulations with PEG 400 displayed lower drug release rate compared to 
conventional tablet. 
Amrit B. Karmarkar et el., 2010, evaluated (in vitro) dissolution profile comparison 
methods of sustained release tramadol hydrochloride with marketed sustained release 
tablets. Liquisolid sustained release formulations were prepared by using HPMC 
K4M as a sustained release agent. Liquisolid compacts were evaluated .The 
dissolution profile followed the Peppas model as “best fit”.  Two-way ANOVA 
results revealed a significant difference in dissolution profiles. This systematic 
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approach to producing a formulation was found to help with analyzing the sustained 
release of tramadol hydrochloride. 
Dinesh M. Pardhi et al., 2010, developed liquisolid technique for enhancement of 
dissolution properties of carvedilol. The invitro release pattern of liquisolid compacts 
and directly compressed tablets were studied using USP-2 apparatus. From this study 
it concludes that the liquisolid technique is a promising alternative for improvement 
of dissolution property of water insoluble drugs. 
Khalid M. El-Say et al., 2010, formulated and evaluated rofecoxib liquisolid tablets. 
The effect of powder substrate composition on the flow ability and compressibility of 
liquisolid compact were evaluated specifically several liquisolid formulation 
containing 25mg rofecoxib using different carrier to coating ratios in their powder 
substrates and fixed liquid medication were prepared. From the previous results, it 
was concluded that addition of 10 % Cab-O-Sil and 5% magnesium oxide improved 
both the flow ability and compressibility of tested rofecoxib powders. These two 
substances change the flow ability from bad flow to satisfactory flow. The prepared 
liquisolid tablets showed higher dissolution profile than the three studied commercial 
tablet. 
Shashibher Burra et al., 2010, enhanced the solubility and dissolution rate of 
furosemide through liquisolid technique. The drug dissolution was tested using 
different dissolution media such as 1.2pH, 5.4pH, 6.8pH, 7.4pH. The results showed 
that liquid solid tablets have higher drug dissolution rates than the conventional and 
directly compressible tablet. 
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Sanjeev raghavendra Gubbi et al., 2010, formulated and characterized atorvastatin 
calcium liquisolid compact were prepared using a mathematical model for calculating 
required quantities of powder and liquid ingredients to produce an acceptably 
flowable and compress able admixture. Avicel PH102, Aerosil 200 and Explotab were 
employed as carrier, coating material and disintegrant respectively. This study shows 
that the liquisolid technique is a promising alternative for improvement of the 
dissolution rate and oral bioavailability of water insoluble drugs confirmed by 
estimating the pharmacokinetic parameters in vivo in rabbits. 
Amrit B. Karmarkar et al., 2009, enhanced dissolution rate of fenofibrate using 
liquisolid tablet technique. Liquid medications such as solutions or suspensions of 
water insoluble drugs in suitable non-volatile liquid vehicles can be easily converted 
into powders with acceptable flow properties and compression behavior by using 
powder excipients. Enhanced drug release profiles due to increased wetting properties 
and surface of drug available for dissolution was obtained in case of liquisolid tablets. 
Amal A. Elkordy et al., 2009, formulated and evaluated the effects of liquisolid 
formulations on dissolution of naproxen with three different liquid vehicles namely 
cremophor EL, synperonic PE/L61 and polyethylene glycol 400 at two drug 
concentrations 20% w/w and 40% w/w. Avicel PH102 was used as a carrier material, 
Cab-O-sil M5 as a coating material, maize starch as a disintegrant. Liquisolid tablets 
formulated with cremophor EL at drug concentration of 20% w/w produced high 
dissolution profile with acceptable tablet properties. 
Sanjeev Gubbi et al., 2009, performed liquisolid technique for enhancement of 
dissolution properties of bromhexine hydrochloride. Different LS compacts were 
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prepared using a mathematical model to calculate the required quantities of powder 
and liquid ingredients to produce acceptably flowable and compressible mixture. The 
prepared LS compacts were evaluated. From this study it was concluded that the LS 
technique is a promising alternative improvement of dissolution property for water 
insoluble drugs. 
 Yadav V.B. et al., 2009, improved solubility and dissolution of indomethacin by 
liquisolid compaction and granulation technique. In the liquisolid system IM was 
dispersed on polyethylene glycol 400(PEG 400) as a non-volatile liquid vehicle. 
Microcrystalline cellulose (Avicel PH102) and dibasic calcium phosphate (DCP) were 
used as a carrier; hydroxypropyl methyl cellulose (HPMC) as coating material and 
sodium starch glycolate (SSG), croscarmellose sodium (CCS) were used as 
disintegrants. It was observed that the drug release rate, water solubility and 
wettability of liquisolid granules containing super disintegrants were on higher side 
compared to liquisolid granules without super disintegrants. 
Ali Nokhodchi et al., 2008, carried out liquisolid technique as a new approach to 
sustain propranolol hydrochloride release from tablet matrices. The drug was 
dispersed in polysorbate 80 as liquid vehicle. Then the binary mixture of eudragit RL 
or RS (carrier) and silica (coating material) was added to the liquid medication under 
continuous mixing in a mortar. The final mixture was compressed using a manual 
tableting machine. The release rate of propranolol HCl from liquisolid compacts was 
compared with that of conventional tablets. The drug prepared by liquisolid technique 
showed greater retardation properties in comparison with conventional tablets. This 
investigation provided evidence that polysorbate 80 (Tween 80) has important role in 
sustaining the release of drug from liquisolid matrices. 
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Ali Nokhodchi et al., 2007, studied liquisolid technique as a tool for enhancement of 
poor water soluble drugs and evaluated their physiochemical properties. Different 
formulations of liquisolid tablets, using different co-solvents, (non-volatile solvents) 
were prepared and the effect of aging on the dissolution behavior of indomethacin 
liquisolid compacts was investigated. Dissolution test was carried out at two different 
pH, 1.2 and 7.2 to simulate the stomach or intestine fluid respectively. Liquisolid 
compacts containing propylene glycol as vehicle produced higher dissolution rates in 
comparison with liquisolid compacts containing PEG 400 or Tween 80 of the same 
concentration. 
Ali Nokhodchi et al., 2007, enhanced the dissolution rate of high dose water 
insoluble drug (carbamazepine) using liquisolid technique. Different liquisolid 
formulations of drug were accomplished by dissolving the drug in the non–toxic 
hydrophilic liquids and adsorbing dissolution on to the surface of silica. In order to 
reduce the amounts of carrier and Aerosil in liquisolid formulations some additives 
namely polyvinyl pyrolidone (PVP), hydroxypropyl methyl cellulose (HPMC) and 
polyethylene glycol (PEG 35000) were added to liquid medication to increase loading 
factor. The effects of various ratios of carrier to coating material, PVP concentration, 
effect of aging and type of carrier on dissolution rate of liquisolid compacts were 
studied. The results showed that drug loading factors was increased significantly in 
the presence of additives. It was shown that microcrystalline cellulose had more liquid 
retention potential in comparison with lactose and the formulations containing 
microcrystalline cellulose as carrier, showed higher dissolution rate. By decreasing 
the ratio of microcrystalline cellulose to silica from 20 to 10, an improvement in 
dissolution rate was observed. 
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Dina Louis et al., 2007, improved the dissolution properties of carbamazepine 
through application of liquisolid tablet technique. Avicel PH 102 and Aerosil 200 
were used as carrier and coating material respectively and Explotab was used as 
disintegrant to prepare four tablet formulae, out of which formula 1 was successfully 
compressed into tablets. The prepared tablets showed good wettability, rapid 
disintegration and acceptable dissolution rate comparable to the generic product. 
 Nokhodchi A. et al., 2005, enhanced the dissolution rate of piroxicam using 
liquisolid compacts. The dissolution behavior of drug from liquisolid compacts was 
investigated in simulated gastric fluid (SGF pH1.2) and simulated intestinal fluid (SIF 
pH7.2). The results showed that liquisolid compacts demonstrated significantly higher 
drug release rates than those of conventionally made. This was due to an increase in 
wetting properties and surface of drug available for dissolution. 
Khaled A. Khaled et al., 2001, evaluated (in vivo) hydrochlorothiazide liquisolid 
tablets in beagle dogs. The drug was administered orally as a single 25mg dose of 
commercial and liquisolid tablets on two occasions in a randomized two-way cross 
over design. The absolute bioavailability of the drug from the liquisolid tablets was 
15% higher than that from the commercial one. The parametric 90% confidence 
intervals for the different parameters were higher than the commonly expected 
intervals for bioequivalency, indicating greater bioavailability of the liquisolid tablets. 
Spiro Spireas et al., 1998, enhanced prednisolone dissolution properties using 
liquisolid compacts. According to the new formulation method of liquisolid compacts, 
liquid medications such as solutions or suspensions of water insoluble drugs in 
suitable non – volatile liquid vehicles can be converted into acceptably flowing and 
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compressible powders by blending with selected powder excipients. Liquisolid 
compacts demonstrated significantly higher drug release rates, in different dissolution 
media and volumes, compared to tablets prepared by the direct compression method. 
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CHAPTER - III 
AIM OF THE WORK 
The poor dissolution rate of water insoluble drug is a major impediment to 
the development of pharmaceutical dosage forms. The oral absorption of drugs is 
most often controlled by dissolution in the gastrointestinal tract. Different methods 
are employed to improve the dissolution characteristics of poorly water soluble 
drugs, like solubilization, pH adjustment, co-solvents, microemulsion, particle size 
reduction, use of surfactant as a solubilizing agent, prodrug approach etc. Amongst 
these the most promising method for promoting dissolution is the use of the 
liquisolid system.  
Liquisolid system refers to formulations formed by conversion of oily liquid 
drugs and solutions or suspensions of water insoluble solid drugs in non-volatile 
solvents into dry, non-adherent, free flowing and compressible powder mixtures by 
blending the suspension or solution with selected carriers and coating materials.     
Schizophrenia is one of the functional disorders of psychosis. No underlying 
cause can be defined for this; memory and orientation are mostly retained but 
emotion, thought and behavior are seriously altered. Schizophrenia is also known as 
the split mind i.e. splitting of perception and interpretation from reality- 
hallucination, inability to think coherently.  
Schizophrenia can be treated by various drugs like risperidone, clozapine, 
olanzapine, haloperidol, trifluperidol, paliperidone etc. Paliperidone is a prescription 
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drug used for the treatment of schizophrenia. Paliperidone belongs to atypical 
antipsychotics. 
Paliperidone is a class II drug of BCS classification; hence it has a low 
solubility and low permeability. Due to the low solubility it has a low oral 
bioavailability. Paliperidone has 28% oral bioavailability. 
            To overcome the drawbacks, various techniques are employed to enhance the 
dissolution of water insoluble drug. Among these the “liquisolid” is a newly 
developed technique. As the drug is in the form of liquid medication, it is in either 
solubilized or molecularly dispersed state. Due to increased wetting and surface area 
for dissolution, liquisolid tablets of water insoluble drugs may show improved 
dissolution properties and in turn increases bioavailability. 
The aim of present study is to formulate liquisolid tablets of paliperidone 
using non-volatile liquid Tween 80, Avicel PH102 as a carrier and Aerosil 200 as a 
coating material. The best formulation selection is on the basis of release pattern and 
is to be compared with directly compressed tablet and pure drug.  
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CHAPTER - IV 
PLAN OF WORK 
 
1. PREPARATION OF STANDARD CALIBRATION CURVE 
 a) Determination of λ max 
b) Preparation of calibration curve 
2. SOLUBILITY STUDIES 
3. PREFORMULATION (COMPATIBILITY) STUDIES 
a) Infrared spectroscopic studies   
4. FLOWABLE LIQUID-RETENTION POTENTIAL (Ф-VALUE) OF 
EXCIPIENTS 
 a) Determination of the angle of slide 
 b) Determination of flowable liquid-retention potential (ф-value) 
5. PROCEDURE FOR PREPARATION OF LIQUISOLID POWDER 
6. PREPARATION OF DIRECTLY COMPRESSED TABLETS 
7. PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
a) Angle of repose 
b) Bulk Density 
c) Tapped Density 
d) Carr’s Index 
e) Hausner’s Ratio 
f) Drug content for Powder Blend 
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8. POSTCOMPRESSIONAL EVALUATION OF LIQUISOLID TABLETS 
            a) General appearance 
            b) Thickness 
            c) Hardness 
            d) Weight variation 
            e) Friability test 
            f) Estimation of drug content    
            g) Disintegration test 
9.  IN VITRO RELEASE STUDIES 
10. POWDER X-RAY DIFFRACTION STUDIES 
11. ASSESSMENT AND COMPARISON OF DRUG DISSOLUTION RATES 
12. SELECTION AND EVALUATION OF BEST FORMULATION 
a) Comparison of dissolution studies of best formulation with pure drug     
    and directly compressed tablets 
b) Infrared spectroscopic studies for best formulation 
            c)  Differential scanning colorimetric (DSC) studies for best formulation 
            d) SEM analysis for best formulation 
            e) Stability studies 
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CHAPTER- V 
MATERIALS AND EQUIPMENTS 
 
MATERIALS DISTRIBUTORS 
Paliperidone Orchid Pharmaceuticals, Chennai. 
Propylene glycol Indian drugs and pharmaceutical limited, 
Hyderabad. 
Polyethylene glycol 400 Central drug house (P) Ltd, New Delhi.  
Tween  80 Himedia Laboratories Pvt Ltd, Mumbai. 
Capryol 90 (propylene glycol 
monocaprylate) 
Gift Samples from Gattefosse India Pvt 
Ltd, Mumbai. 
Talc  Nice chemicals, Kochi. 
Microcrystalline cellulose Central drug house (P) Ltd, New Delhi. 
Aerosil 200 (silica) Pharmafabrikon, Madurai. 
Sodium starch glycolate Pharmafabrikon, Madurai. 
Magnesium stearate Central drug house (P) Ltd, New Delhi. 
Methanol  Astron Chemicals, Ahmedabad. 
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EQUIPMENTS SUPPLIERS 
Electronic Weighing Balance A&D Company, Japan. 
Single punch tablet compression 
machine 
Cadmach Machinery Co.Pvt,     
Ahmadabad. 
UV Visible spectrophotometer Shimazdu UV-1700, Japan. 
Digital tablet dissolution test apparatus  Lab India Disso apparatus 2000, India. 
Friability test apparatus Indian Equipment corporation, Mumbai. 
Tablet hardness tester Praveen Enterprises, Bangalore. 
Vernier caliper Linker, Mumbai. 
Disintegration  test apparatus Rolex, India. 
Fourier transform infrared spectroscopy Shimadzu, Japan. 
Differential  scanning colorimeter DSC Q200 V24.4 Instrument, USA. 
Powder X-ray diffractometer XD, Shimadzu, Japan. 
Scanning electron microscopy Hitachi X650, Tokyo, Japan 
Magnetic stirrer M.C.Dalal, Chennai. 
Mechanical shaker Secor, India. 
Environmental Chamber Inlab Equipments (P) Ltd, Madras. 
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hexane; and slightly soluble in N, N-
dimethylformamide. 
Molecular weight   : 426.49 g/mol 
pKa      :  0 
Log P             :  1.76 
Refractivity            : 116.04   
Melting point          :  168° C 
Polarizability           : 45.95 
MECHANISM OF ACTION 
Paliperidone is the primary active metabolite of the older antipsychotic 
risperidone. While its specific mechanism of action is unknown, it is believed that 
paliperidone and risperidone act via similar if not the same pathways. It has been 
proposed that the drug’s therapeutic activity in schizophrenia is mediated through a 
combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) 
receptor antagonism.  
Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic 
receptors and H1 histaminergic receptors, which may explain some of the other 
effects of the drug.  
PHARMACOKINETICS  
Absorption  
 The absolute oral bioavailability of paliperidone following paliperidone 
administration is 28%.  
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Volume of distribution 
 Mean volume of distribution at steady-state of paliperidone is approximately 
487 liters. 
Protein binding  
The plasma protein binding of racemic paliperidone is 74%. 
Metabolism 
Although in vitro studies suggested a role for CYP2D6 and CYP3A4 in the 
metabolism of paliperidone, in vivo results indicate that these isozymes play a limited 
role in the overall elimination of paliperidone. Four primary metabolic pathways have 
been identified in vivo, none of which could be shown to account for more than 10% 
of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole 
scission. Paliperidone does not undergo extensive metabolism and a significant 
portion of its metabolism occurs in the kidneys. 
Route of elimination 
One week following administration of a single oral dose of 1 mg immediate-
release 14C-Paliperidone to 5 healthy volunteers, 59% (range 51% – 67%) of the dose 
was excreted unchanged into urine, 32% (26% – 41%) of the dose was recovered as 
metabolites, and 6% – 12% of the dose was not recovered. 
HALF LIFE 
            The terminal elimination half life of paliperidone is approximately 23 hours. 
INDICATIONS AND USAGE 
Paliperidone is indicated for the treatment of schizophrenia including acute 
treatment and recurrence prevention. It is also indicated for the treatment of acute 
exacerbations of schizoaffective disorder as monotherapy and in combination with 
antidepressants and or mood stabilizers (lithium and valproate). 
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DOSAGE AND ADMINISTRATION 
            1.5 mg to 12 mg.  The recommended dose for the treatment of schizophrenia 
is 6 mg once daily, administered in the morning. Some patients may benefit from 
lower or higher doses within the usual range of 3 mg to 9 mg once daily. Dose 
increases above 6 mg 1 day should be made only after clinical reassessment and 
generally should occur at intervals of more than 5 days. When dose increases are 
indicated, small increments of 3 mg/day are recommended. If required the dose may 
be increased to the maximum recommended dose of 12 mg once daily. 
            Injection 25 mg to 150 mg monthly.  
DOSAGE FORMS 
Tablet, extended release - Oral 3 mg 
Tablet, extended release - Oral 6 mg 
Tablet, extended release - Oral 9 mg 
CONTRAINDICATIONS 
           Hypersensitivity to paliperidone or risperidone 
 ADVERSE REACTIONS  
 Tachycardia  
 Headache  
 Somnolence  
 Hyperprolactinemia  
 Akathisia  
 Orthostatic hypotension 
 Parkinsonism   
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 Dizziness 
 Weight gain  
 Hyperkinesia  
 Dose dependent dyskinesia   
 Abdominal pain 
 Tremor 
 Dry mouth 
 Hypersalivation 
 Vomiting 
OVERDOSAGE 
While experience with paliperidone overdose is limited, among the few cases 
of overdose reported in pre-marketing trials, the highest estimated ingestion of 405 
mg. Observed signs and symptoms included extrapyramidal symptoms and gait 
unsteadiness. Other potential signs and symptoms include those resulting from an 
exaggeration of paliperidone’s known pharmacological effects, i.e., drowsiness and 
somnolence, tachycardia and hypotension and QT prolongation. 
DRUG INTERACTIONS 
 Centrally-acting drugs: Due to CNS effects, use caution in combination. 
Avoid alcohol. 
 Drugs that may cause orthostatic hypotension: An additive effect may be 
observed when co-administered with Paliperidone.  
 
CHAPTER VI                                                                                     DRUG PROFILE 
 
Liquisolid tablets of Paliperidone Reg. No. 261211302 Page 47 
 
 Co-administration with Carbamazepine decreased mean steady-state Cmax 
and AUC of Paliperidone by approximately 37%. Adjust dose of Paliperidone 
if necessary based on clinical assessment.  
 Co-administration of Divalproex sodium increased Cmax and AUC of 
Paliperidone by approximately 50%. Adjust dose of Paliperidone, if necessary 
based on clinical assessment. 
 
BRAND NAMES 
Invega (Janssen-Cilag, UK) 
Palido- OD (Torrent Pharmaceuticals Ltd, India) 
Palip- XR (Intas Pharmaceuticals Ltd, India). 
(www. drugbank.com, www.fda.gov, www.mims.com) 
(Martindale, 36th ed, The complete drug reference) 
CHAPTER VII 
 
 
 
 
 
 
 
 
 
 
 
EXCIPIENTS PROFILE 
 
CHAPTER VII                                                                           EXCIPIENT PROFILE 
 
Liquisolid tablets of Paliperidone Reg. No. 261211302 Page 48 
 
CHAPTER -VII 
EXCIPIENT PROFILE 
TWEEN 80 
Synonyms 
 Armotan PMO 20 
 Capmul POE-O 
 Cremophor Ps 80 
 Montanox 80 
 Polyoxyethylene 20 oleate 
Chemical name 
 Polyoxyethylene 20 sorbitan monooleate              
 
Empirical formula 
 C64  H24  O26 
Molecular weight 
 1310  
Functional Category 
 Emulsifying agent 
 Non ionic surfactant 
 Solubilizing agent 
 Wetting agent  
 Dispersing/ suspending agent 
HLB value 
 15 
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Stability and storage condition 
 Polysorbates are stable to electrolytes and weak acids and bases. 
 Polysorbates should be stored in a well-closed container, protected from light, 
in a cool, dry place. 
Incompatibilities 
 The antimicrobial activity of paraben preservatives is reduced in the presence 
of polysorbates. 
Handling Precautions 
 Observe normal precautions appropriate to the circumstances and quality of 
material handled. Eye protection and gloves are recommended. 
.          (Raymond C Rowe., 5th Edition) 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER
 
Liquisolid t
 
Synonyms 
 1,2-
 2-hy
 Met
 Met
 Prop
Chemical n
 1,2-
Empirical 
 C3 H
Molecular 
 76.0
Structural
HLB value
 11.6
Functional
 Ant
 Disi
 Hum
 VII           
ablets of Pa
Dihydroxyp
droxyprop
hyl ethylen
hyl glycol 
ane-1,2-di
ame 
 Propanedi
formula 
8 O2 
weight 
9 
 formula 
 
 
 Category 
imicrobial P
nfectant 
ectants 
                  
liperidone R
PRO
ropane 
anol 
e glycol 
ol 
ol 
reservative
                  
eg. No. 261
 
PYLENE
s 
                  
211302
 GLYCOL
          EXC
 
 
IPIENT PROFILE 
Page 51 
 
CHAPTER VII                                                                           EXCIPIENT PROFILE 
 
Liquisolid tablets of Paliperidone Reg. No. 261211302 Page 52 
 
 Plasticizer 
 Solvents 
 Water – Miscible cosolvents 
Application in pharmaceutical formulation or technology 
 Propylene glycol has become widely used as a solvent, extractant and 
preservative in a variety of parenteral and nonparenteral pharmaceutical 
formulations 
 Propylene glycol is commonly used as a plasticizer in aqueous film-coating 
formulations; 
 Propylene glycol is also used in cosmetics and in the food industry as a carrier 
for emulsifiers and as a vehicle for flavors in preference to ethanol, since its 
lack of volatility provides a more uniform flavor. 
Description 
 Propylene glycol is a clear, colorless, viscous, practically odorless liquid with 
a sweet, slightly acrid taste resembling that of glycerin. 
Melting Point 
 - 59oC 
Solubility 
 Soluble in acetone, chloroform, ethanol, glycerin and water. 
Viscosity at 25o C 
 58.1 mPas 
Stability and storage condition 
 Propylene glycol is chemically stable when mixed with ethanol (95%), 
glycerin, or water. 
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 Propylene glycol is hygroscopic and should be stored in a well-closed 
container, protected from light, in a cool, dry place. 
Incompatibilities 
 Propylene glycol is incompatible with oxidizing reagents such as potassium 
permanganate. 
Handling Precautions: 
 Propylene glycol should be handled in a well-ventilated environment; eye 
protection is recommended.   
(Raymond C Rowe., 5th Edition) 
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Description 
 Clear liquid, odourless. 
Melting Point 
 4°C (39.2°F) 
Solubility 
 Soluble in cold water, hot water. Slightly soluble in aliphatic hydrocarbons. 
Readily soluble in aromatic hydrocarbons. 
Stability 
 Stable under ordinary condition, hygroscopic. 
Storage 
 Tightly closed container. Keep container in a cool, well-ventilated area. 
Precautions 
 Keep away from heat, source of ignition and incompatibles such as oxidizing 
agents, acids, alkalis. 
 Wear suitable protective clothing. 
(www.sciencelab.com and Raymond C Rowe., 5th Edition) 
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      Oral: A water insoluble surfactant, used in self emulsifying systems to obtain a 
coarse dispersion and bioavailability enhancer. 
      Topical: A water-in-oil surfactant/solubilizer.  
Formulation techniques and dosage forms 
 Suitable for soft and hard gelatin capsules. 
 Use in topical ointments, microemulsions and emulsions. 
Storage 
 Stable under ordinary condition. 
Application 
 It is used as a lipophilic emulsifier and emulsion stabilizer in food and 
personal care products.  
(www.chemicalland21.com) 
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 Tablet disintegrant 
Application in pharmaceutical formulation or technology 
  Microcrystalline cellulose is widely used in pharmaceuticals primarily as 
binder/diluents in oral tablet and capsule formulation. 
 It is used as binder/diluents. 
 Microcrystalline cellulose is also used in cosmetics and food products. 
Description 
 Microcrystalline cellulose is a white, odorless, tasteless, crystalline powder 
composed of porous particles. 
.Melting Point 
 260-270oC 
Solubility 
 Slightly soluble in 5% w/v NaOH solution, practically insoluble in water and 
most organic solvents. 
Stability and storage condition 
 Microcrystalline cellulose is stable though hygroscopic material. 
 It should be stored in a well-closed container in a cool, dry place. 
Incompatibilities 
 Microcrystalline cellulose is incompatible with strong oxidizing agent. 
Handling Precautions 
 Microcrystalline cellulose may be irritant to the eyes. Gloves, eye protection 
and dust mask are recommended. 
          (Raymond C Rowe., 5th Edition) 
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SILICA 
Synonyms 
 Aerosil 
 Cab-O-sil 
 Colloidal silica 
 Fumed silica 
 Fumed silicon dioxide 
 Silicone dioxide colloidal 
Chemical name 
 Silicon dioxide              
Empirical formula 
 SiO2 
Molecular weight 
 60.08 
Functional Category 
 Adsorbent 
 Anticaking agent 
 Glidant and Tablet disintegrant 
  Emulsion stabilizer 
 Viscosity increasing agent 
Application in pharmaceutical formulation or technology 
  It is improves the flow properties of the dry powders.   
 It is used as an adsorbent dispersing agent for liquids in powders. 
 Eliminate hard settling and minimize the clogging of spray nozzle. 
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Description 
 Colloidal silicone dioxide is a light, loose, bluish-white coloured, tasteless, 
odorless and amorphous powder.  
Melting Point     
 1600oC  
Solubility 
 Soluble in hot solution of alkali hydroxide. Practically insoluble in water, 
organic solvents and acids. 
 Storage condition 
 It should be stored in a well closed container.  
Incompatibilities 
 It is incompatibility with diethylstilbestrol preparations. 
Handling Precautions 
 A dust mask should be used, when handling small quantity.  For large 
quantities, a dust respirator is recommended. 
  (www.chemicallab.com and Raymond C Rowe., 5th Edition) 
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Melting Point 
 Does not melt, but chars at approximately 200oC. 
Solubility 
 Practically insoluble in methylene chloride   
Storage condition 
 It should be stored in a well closed container in order to protect it from 
temperature and humidity. 
Incompatibilities 
 Sodium starch glycolate is incompatible with ascorbic acid 
Handling Precautions 
 Eye protection, gloves, dust mask or respirator is recommended. 
      (Raymond C Rowe., 5th Edition) 
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MAGNESIUM STEARATE 
Synonyms: 
 Magnesium distearate 
 Dibasic magnesium stearate 
 Octadecanoic acid, magnesium salts 
 Magnesium octadecanoate 
Chemical name 
   Octadecanoic acid magnesium salt            
 
Empirical formula 
 C36 H70MgO4 
Molecular weight 
 591.24 
Structural formula 
 [CH(CH2)16COO]2Mg 
Functional Category 
 Tablet and capsule lubricant. 
Application in pharmaceutical formulation or technology 
 It is used as a lubricant in tablet and capsule formulation.  
 It is widely used in foods, cosmetics and pharmaceutical formulations. 
Description 
 Magnesium stearate is a very fine, light white. 
 The powder is greasy to the touch and readily adheres to the skin. 
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Melting Point 
 117-150oC 
Solubility 
 Slightly soluble in warm benzene and warm ethanol. 
 Practically insoluble in ethanol and water. 
Storage condition 
 It should be stored in a well-closed container in a cool and dry place. 
Incompatibilities 
 Incompatible with strong acids, alkalis and iron salts. 
 Magnesium stearate cannot be used in product containing aspirin and some 
vitamins. 
Handling Precautions 
 Eye protection and gloves recommended. 
Magnesium stearate should be handled in a well-ventilated environment; a 
respirator is recommended  
(Raymond C Rowe., 5th Edition). 
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Description 
 Talc is a very fine, white to grayish – white, odorless. 
 It adheres readily to the skin and is soft to the touch and free from grittiness. 
Melting Point 
 800oC 
Solubility 
 Practically insoluble in organic solvents, water and in dilute acids & alkalis.  
Stability and storage condition 
 Talc is stable material and may be sterilized by heat in at 160oC for not less 
than one hour and also sterilized by exposure to ethylene oxide or gamma 
irradiation. 
 It should be stored in a well-closed container in a cool and dry place. 
Incompatibilities 
 Incompatible with quaternary ammonium compounds.  
Handling Precautions 
 Talc is irritant if inhaled and prolonged excessive exposure may cause 
pneumoconiosis. 
 Eye protection, gloves and respirator is recommended. 
(Raymond C Rowe., 5th Edition) 
CHAPTER VIII 
 
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL DETAILS 
 
CHAPTER VIII                                                               EXPERIMENTAL DETAILS 
 
Liquisolid tablets of Paliperidone Reg. No. 261211302 Page 68 
 
CHAPTER - VIII 
EXPERIMENTAL DETAILS 
1. PREPARATION OF STANDARD CALIBRATION CURVE  
a) Determination of λ max 
           A known weight (100 mg) of drug (Paliperidone) is dissolved in 25ml of 
methanol and diluted to 100ml using a distilled water to form a primary stock solution 
(1000µg/ml). The stock solution is further diluted using distilled water to 10µg/ml 
concentration. The resultant solution is scanned in the range of (200-400nm) by Ultra 
visible Spectrophotometer (UV-1700 Shimadzu corporation, Japan) to get absorption 
maximum (λ max) (Anuja Pandey et al., 2013 and Vinay Kumar et al., 2012). 
b) Preparation of Calibration Curve 
From the above prepared stock solution, different concentration (1 to 
10µg/ml) solutions are prepared using distilled water. The absorbances of these 
solutions are measured at λmax (237nm) by UV- spectrophotometer (UV-1700 
Shimadzu Corporation, Japan). A standard curve is plotted using concentration on X-
axis and the absorbance obtained on Y-axis. 
2. SOLUBILITY STUDIES: 
           Solubility studies of Paliperidone is carried out in Propylene glycol, 
Polyethylene glycol 400 (PEG 400), Tween 80, Capryol 90 and in distilled water. 
Saturated solutions are prepared by adding excess drug to the vehicles and shaking on 
the shaker for 48 hours at 25 ± 0.5 0C under constant vibration. After this period the 
solutions are filtered, diluted and analysed by UV Spectrophotometer. Three 
determinations are carried out for each sample to calculate the solubility of 
Paliperidone (Jabbar et al., 2013). 
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3. PREFORMULATION (COMPATIBILITY) STUDIES 
The compatibility studies are carried out by infrared spectroscopic studies (IR) 
in order to evaluate the drug and polymer interaction. 
a) Infrared spectroscopic Studies 
Infrared spectra of pure drug, carrier and coating materials are obtained with a 
Shimadzu, Japan. Samples are prepared in KBr disks (2mg sample in 200mg KBr).  
The scanning range is 4000 to 400 cm-1 (Vinay kumar et al., 2012). 
4. FLOWABLE LIQUID-RETENTION POTENTIAL (Φ-VALUE) OF THE 
EXCIPIENTS (AVICEL PH 102 AND AEROSIL 200) 
a)  Determination of the angle of slide 
The Angle of slide for carrier and coating material (10 gm of Avicel PH 102 
and Aerosil 200) is measured as follows: 
The excipients are weighed accurately and placed at one end of a metal plate 
with a polished surface. This end is raised gradually until the plate made an angle 
with the horizontal at which as a measure for the flow characters of powders. An 
angle of slide θ corresponding to 33°corresponded to optimal flow properties (Shah et 
al., 2012, A. A. Elkordy et al., 2012 and Dina Louis et al., 2008). 
b)  Determination of flowable liquid-retention potential (φ-value)  
To the 10 g of excipients, increasing amounts of liquid vehicle are added and 
mixed well. The excipients adsorbed liquid vehicle resulting in a change in its flow 
properties. At each concentration of liquid vehicle added, the angle of slide θ for 
excipients are re-determined as stated above. The corresponding Φ-value is calculated 
from the following equation. 
Φ-value = weight of liquid/weight of solid 
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The Φ-values are plotted graphically against the corresponding angles of slide 
(h). The Φ-value corresponding to an angle of slide of 33° represented the flowable 
liquid-retention potential of excipients. 
The Φ-value for Avicel PH 102 and Aerosil 200 is reported in the table below 
and hence there is no need to determine it practically (Amal Ali Elkordy et al., 2013 
and Dina Louis et al., 2008) 
Table 3: Φ–values for carrier material and coating material 
(Spireas et al., 1998 and Abdul Hasan Sathali A. and Deepa C. et al., 2013) 
Non-Volatile liquid 
Vehicles 
Φ-value for carrier 
material (Avicel PH102) 
Φ-value for coating 
material (Aerosil 200) 
1.Propylene glycol 0.16 3.31 
2.polyethylene glycol400 0.005 3.26 
3.Tween 80 0.003 3.95 
4.Cremophor EL 0.18 0.80 
5.capryol 90 0.16 0.40 
These values are used for the preparation of liquisolid tablets. 
5. PROCEDURE FOR PREPARATION OF LIQUISOLID SYSTEM 
           Several Paliperidone liquisolid formulations are prepared in batches of 60 
tablets at different ratios of (1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10) drug: liquid 
vehicles. Each formulation contains Avicel PH102 as carrier and Aerosil 200 as 
coating material, at carrier/coat ratio(R value) of 20 and 30. The appropriate amounts 
of carrier and coating materials used for each formulation depend upon Lf of that 
formulation. The ΦCa and ΦC0 values for each particular liquid vehicle are used to 
calculate Lf [Eq- (1)] of that respective liquid vehicle. Once the liquid load factor (Lf) 
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and amount of liquid medication (W) are determined amount of carrier (Q) and 
coating (q) can be calculated by rearranging Eq- (2) and (3) 
                                 Lf = ΦCa + ΦC0 × 1/R                                (1) 
                                 Lf = W/Q               (2) 
                                 R = Q/q                                                        (3) 
           The drug-vehicle liquid system is produced by mixing Paliperidone (6mg/ 
tablet) in non-volatile liquid vehicle using a mortar and pestle. To this liquid 
medication, the calculated amount of the carrier (Avicel PH102) is added by 
continuous mixing in the mortar. Then the coating material (Aerosil 200) is carefully 
added and mixed until mortar contents start to look like dry powder. In the last stage 
of the preparation, a 5% (w/w) sodium starch glycolate as a super disintegrant and 
0.75% (w/w) of magnesium stearate as a lubricant are added and mixed. All liquisolid 
preparations are compacted into tablets using a single punch tablet machine (Cadmah, 
Mumbai) having 10mm flat punch. The applied compression force is different from 
one formulation to another formulation depending on the weight of the tablet and the 
preparation (Dinesh M. Pardhi et al., 2010 and Spiro Spireas et al., 1998). 
6. PREPARATION OF DIRECTLY COMPRESSED TABLETS  
          For comparison conventional Paliperidone (6mg/tablet) are prepared by mixing 
all tablet excipients, except non-volatile liquid vehicle compressed into tablets (Amal 
Ali Elkordy et al., 2012 and Spiro Spireas et al., 1998).   
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Table 4: Composition of directly compressed tablets 
S. No Ingredients 
Quantity for one 
tablet (mg) 
1. Paliperidone 6 
2. Avicel PH102 490.09 
3. Aerosil 200 16.33 
4. Sodium starch glycolate 25.62 
5. Magnesium stearate 4.03 
                                                                          Total Weight = 542.07mg 
7. PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
 a) Angle of repose  
Angle of repose is defined as the maximum angle possible between the 
surface of a pile of the powder and the horizontal plane. In this method, a fixed funnel 
method procedure is performed in triplicate and average angle of repose calculated 
(Kamalakanan V. et al., 2012 and Aulton M.E., 2002). 
                                                  tan θ = h/r   
Where, 
                  θ = angle of repose 
                  h = height of pile 
                  r = radius of pile 
The relationship between the angle of repose and powder flow is as follow in 
the table: 
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Table 5: Limits for angle of repose 
ANGLE OF REPOSE POWDER FLOW 
                 < 25o Excellent 
               25-30 o Good 
              30-40o Passable 
                 >40o Very poor 
 
b) Bulk density 
Bulk density is the ratio between given mass of powder and its bulk volume. 
Bulk density is carried out in triplicate. Bulk density measurements are carried by 
placing fixed weight of powder in graduated cylinder and volume occupied is 
measured and initial bulk density is calculated.  It is expressed in gm/ml. Bulk density 
is calculated by using following formula (Kamalakanan V. et al., 2012 and Pradeep 
Yala et al., 2012) 
                                                    Mass of the powder 
                 Bulk Density = 
                                               Bulk volume of the powder 
c) True density 
True density is the ratio between given mass of powder and constant volume 
of powder after tapping. True density measurements are carried by cylinder is then 
tapped at a constant velocity till a constant volume is obtained. Then tapped density is 
calculated by using following formula (Kamalakanan V. et al., 2012 and Pradeep 
Yala et al., 2012) 
                                                      Mass of the powder 
                 True Density = 
                                               Tapped volume of the powder 
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d) Carr’s Index 
Flowability is assessed from Carr’s compressibility Index (CI %). The CI is 
calculated from the poured (bulk density) and tapped densities. Tapped density is 
measured by tapping fixed weight of the sample into 100 ml measuring cylinder 
several times using a tap density apparatus till a constant volume is obtained, where 
the powder is considered to reach to its most stable arrangement. Carr’s 
compressibility index is then calculated using the following Equation (Devendra 
Revanand Rane et al., 2012 and Aulton M.E., 2002) 
                              Tapped density – Bulk density  
Carr’s Index =                                                             x 100 
                                                    Tapped density 
The smaller the value of the CI%, the superior the flow properties of the powder 
Table 6: Values of Carr’s Index 
CARR’S INDEX TYPE OF FLOW 
5 – 15 % Excellent 
15 -25 % Good 
>25 % Poor 
 
e) Hausner’s Ratio 
               Hausner’s ratio is the ratio of tapped density to bulk density. Lower the 
value of Hausner’s ratio better is the flow property. It is calculated by the following 
formula 
                                                              Tapped Density 
                     Hausner’s Ratio =                             
                                                               Bulk Density 
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Values less than 1.25 indicate good flow (=20% carr), and greater than 1.25 
indicates poor flow (=33% carr). Between 1.25 and 1.5, added glidant normally 
improves flow (Devendra Revanand Rane et al., 2012 and Aulton M.E., 2002). 
f) Drug content 
           The Powder blend containing 10 mg equivalent of drug weighed and dissolved 
in methanol, then the volume is made upto 100ml with distilled water. From the 
above solution, 10 ml is taken and diluted with distilled water. The absorbance of 
resulting solution is measured at 237 nm using UV spectrophotometer (Shimadzu 
UV-1700 pharma spec, Japan) and the drug content is estimated.  
8. POSTCOMPRESSIONAL EVALUATION OF LIQUISOLID TABLETS 
a) General appearance 
The formulated tablets are evaluated for general appearance such as colour, 
shape and appearance (Prasanth Sai R.V et al., 2011). 
b)  Thickness 
            Three tablets are randomly selected from each formulations and thickness is 
measured individually by vernier caliper. It is expressed in millimeter (mm) and 
average is calculated (Amit modi et al., 2012). 
c)  Hardness 
           Tablet requires a certain amount of hardness and resistance to friability to 
withstand mechanical shakes of handling in manufacture, packing and shipping. The 
hardness of the tablets is determined using Monsanto hardness tester. It is expressed 
in Kg/cm2. Three tablets are randomly selected from each formulation and hardness 
of the tablets is determined. The results are expressed in average value (Dnyanesh 
walunj et al., 2012). 
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d) Weight variation 
          Twenty tablets are randomly selected from each formulation and average is 
determined. Then individual tablet are weighed and individual is compared with 
average weight. The tablet pass the USP test if no more that 2 tablets are outside the 
percentage limit and if no tablet differs by more than 2 times the percentage limit 
(Sanjeev Raghavendra Gubbi et al., 2010) 
Table 7: Limits for weight variation test 
AVERAGE WEIGHT
MAXIMUM % DIFFERENCE 
ALLOWED 
130 mg or less ± 10   % 
130 mg to 324 mg ± 7.5  % 
More than 324 mg ± 5    % 
 
e)  Friability test 
            The friability of tablets is determined using Roche friabilator. Twenty tablets 
are randomly selected from each formulation and initial weight of 20 tablets are 
calculated and then transferred into friabilator. The friabilator is operated at 25 rpm 
for 4 minutes (100 revolutions). The tablets are dedusted and weighed again (final 
weight). The percentage friability is calculated by the following equation      
                              
                                       Initial weight – Final weight  
                           F =                                                        × 100 
                                                  Final weight 
Compress tablet that lose less than 0.1 to 0.8% of the tablet weight are 
consider acceptable (Anand Kishore et al., 2011). 
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f) Drug content 
          The total amount of drug present in the liquisolid formulation is evaluated 
using UV-spectrophotometric analysis. Approximately weighed quantity of 10mg 
equivalent of drug is taken from liquisolid formulation which is dissolved in 10ml of 
methanol and the volume is made upto 100ml with distilled water. From the above 
solution, 10 ml is taken and diluted with distilled water. The absorbance of resulting 
solution (10µg/ml) is measured at 237 nm using spectrophotometer (shimadzu UV-
1700  pharma spec, Japan) and the drug content is calculated from the standard curve 
using the formula (Srinivas Vaskula et al., 2012). 
                                                          Sample absorbance 
                            Drug content =                                            x 100 
                                                          Standard absorbance 
g) Disintegration test 
           Disintegration is defined as that state in which no residue of the tablet or 
capsule remains on the screen of the apparatus. The disintegration time of the 
liquisolid tablets is determined using disintegration test apparatus.  Introduce one 
tablet into each tube and floating of the tablets can be prevented by placing a 
perforated plastic disc to each tube. Suspend the basket rack in the beaker containing 
the 900 ml of distilled water at 37 C and move the basket containing the tablets up 
and down through a distance of 5-6 cm at a frequency of 28-32 cycles per minutes 
and  the disintegration time for each formulations is noted (Indian Pharmacopoeia., 
1996. Page no: A-80 to A-81). 
Disintegration time 
a) Uncoated tablets:  5- 30 minutes 
b) Coated tablets:  1-2 hours 
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9. IN VITRO RELEASE STUDIES 
           In vitro  release studies is performed by using USP type II Paddle dissolution 
apparatus in 900 ml of  distilled water maintained at 37° C ± 0.5° C and  rotation 
speed of 50 rpm. Samples (5 ml) are withdrawn at suitable time intervals (5, 10, 15, 
20, 25, 30, 45, 60 minutes) and filtered through whatman filter paper. Sink conditions 
are maintained throughout the study. The withdrawn samples are analyzed by UV- 
visible spectrophotometer (Shimadzu UV-1700 pharma spec, Japan) at λ max of 
237nm. The studies are done in triplicate (Dinesh M. Pardhi et al., 2010 and 
www.fda.gov). 
10. POWDER X-RAY DIFFRACTION STUDIES 
  Powder X-ray diffraction pattern of Paliperidone, Avicel PH102, Aerosil 200 
and liquisolid formulation (Best formulation) are studied using X-ray diffractometer 
(XRD-462, Digaku, Japan) with CuKα radiation. Voltage and current are set 40 kV 
and 30 mA respectively. All pattern scanned over range 5-70o 2θ angle with a scan 
speed of 10o/min (Hirokazu Matsunaga et al., 1999). 
11. ASSESSMENT AND COMPARISON OF DRUG DISSOLUTION RATES 
 The dissolution rate of Paliperidone is the amount of drug (in µg ) dissolved 
per minute by each tablet formulation during first 10 min is calculated by the 
following equation (Shashidher Burra et al., 2011 and Nokhodchi A et al., 2005) 
                                                       (M x D) 
                                       DR = 
                                                         1000 
Where, 
          M = Total amount of pure drug in each tablet (in µg) 
          D = Percentage of drug dissolved in the first 10 minutes 
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12. SELECTION AND EVALUATION OF BEST FORMULATION 
The best formulation is selected depending on the results obtained from 
solubility studies in various non-volatile liquid vehicles and in vitro release studies. 
a)  Comparison with directly compressed tablets 
The in vitro release of best formulation is compared with directly compressed 
tablets are prepared by mixing all tablet excipients, except non-volatile liquid vehicle                         
(Amal Ali Elkordy et al., 2012 and Spiro Spireas et al., 1998). 
b)  Infrared spectroscopic studies for best formulation 
Liquisolid formulation (Best formulation) is subjected to infrared 
Spectroscopic studies as per the procedure already discussed in compatibility studies. 
c) Differential Scanning Colorimetric (DSC) studies for best formulation 
Thermal curves of pure drug, carrier, coating material and liquisolid 
formulation (Best formulation) are recorded by simultaneous differential scanning 
calorimeter (DSC Q200 V24.4 Build 116). Each sample (approximately 2.5mg) are 
scanned in hermetic pan made of aluminium at heating rate of 10° C / min over the 
range of 50° C - 220° C with an empty aluminium pan used as reference. Samples are 
heated under nitrogen atmosphere (flow rate of N2 – 50 ml / min) (Anuja pandey et 
al., 2013 and Abdul Hasan Sathali A. and Gopinath M. et al., 2013).  
d)  SEM analysis for best formulation 
  SEM is used to assess the morphological characteristics of the final liquisolid 
compacts. The samples are fixed on aluminium stubs with double-sided tape, gold 
coated sputter examined in the microscope using an accelerating voltage of 15 KV, at 
a working distance of 8 mm and magnification of X10000 (Pradeep Yala et al., 
2012). 
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e) Stability studies               
              The best formulation of three batches is stored at 40° C ± 2°C and relative 
RH 75% ± 5% for two months.  The best formulation is evaluated using dissolution 
test, drug content, physical appearance, hardness and thickness.  The above tests of 
best formulations are compared with those of freshly prepared tablets (Prasanth Sai 
R.V et al., 2011 and Amit Modi et al., 2012). 
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CHAPTER - IX 
RESULTS AND DISCUSSION 
 
1. PREPARATION OF STANDARD CALIBRATION CURVE 
 The λmax of paliperidone was determined by scanning the (10µg/ml) solution 
of drug in distilled water by UV-spectrophotometer and it was found to be 237 nm 
(Anuja pandey et al., 2013 and Pandey A et al., 2013) (Figure 4).  The absorbance of 
the solution (1-10 µg/ml) was measured in UV-spectrophotometer at 237 nm. The 
linear correlation coefficient was found to be γ = 0.9998. The results were shown in 
Table 8 and the calibration graph of paliperidone was shown in Figure 5. 
2. SOLUBILITY STUDIES 
 The solubility of paliperidone was determined in various non-volatile liquid 
vehicles such as Propylene glycol (PG), Polyethylene glycol (PEG 400), Tween 80, 
Capryol 90 and in distilled water shown in Table 9 and Figure 6. From the results, it 
was observed that the solubility of drug in Tween 80 was higher when compared with 
other liquid vehicles which may be due to the high viscosity and HLB value (Pande 
V. V et al ., 2013 ). 
3. PREFORMULATION (COMPATIBILITY) STUDIES 
a) Infrared Spectroscopic Studies 
Infrared (IR) spectroscopic studies were carried out to confirm the 
compatibility between drug and excipients used for the preparation of liquisolid 
tablets. The IR studies were performed for paliperidone (pure drug), non-volatile 
liquid vehicle, microcrystalline cellulose, aerosil 200 and physical mixture of drug 
and excipients. The spectra studied at 4000cm-1 to 400 cm-1 were shown in Figure 7a 
to 7e.  
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The principal peaks for pure drug were observed at wave numbers 3294.79 
cm-1, 2934.94 cm-1, 1630.56 cm-1, 1534.61 cm-1, 1445.03 cm-1, 1338.91 cm-1, 1271.49 
cm-1, 1129.66 cm-1, 956.84 cm-1, 867.3 cm-1. 
Further in the physical mixtures, all the above characteristics peaks of the 
drug appear in the spectrum, which indicated that there was no interaction between 
the drug and polymers in the physical mixture. 
4. FLOWABLE LIQUID-RETENTION POTENTIAL (Φ-VALUE) FOR 
EXCIPIENTS 
 Angle of slide was used to determine the Φ-value for the excipients (which are 
needed for calculation of the Lf). The ΦCA-value (carrier) and ΦCO-value (coating 
material) decided the appropriate quantities of carrier and coating materials required 
to convert a given amount of liquid medication into a dry-looking, free flowing and 
readily compressible liquisolid formulation.  Flowable liquid-retention potential 
values for excipients were taken from literature (Spireas et al., 1998) 
 The flowable liquid-retention potential (Φ-value) for Avicel PH102 (carrier) in 
Tween 80 was approximately 0.003. 
The flowable liquid-retention potential (Φ-value) for Aerosil 200 (coating 
material) in Tween 80 was approximately 3.95. 
The relatively high Φ -value is advantageous as it results in smaller sizes of 
the tablets. The above values were used to formulate liquisolid tablets of Paliperidone 
(Amal Ali Elkordy et al., 2013). 
5. PROCEDURE FOR PREPARATION OF LIQUISOLID POWDER 
Liquisolid powder of paliperidone were prepared using non-volatile liquid 
vehicle Tween 80 at different ratios of (1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10) 
drug: liquid vehicles. The microcrystalline cellulose (Avicel PH102) was used as a 
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carrier and silica (Aerosil 200) as coating material. Finally 5% (w/w) sodium starch 
glycolate as a super disintegrant and 0.75% (w/w) of magnesium stearate as a 
lubricant were added and mixed. All liquisolid preparations were compacted into 
tablets using a single punch tablet machine (Cadmah, Mumbai) having 10mm flat 
punch. The compositions of all the formulations were given in Table 10A and 10B.  
Twenty formulations (F1- F20) were prepared. 
6. PREPARATION OF DIRECTLY COMPRESSED TABLETS 
A conventional formulation of paliperidone were prepared by using drug 
(Paliperidone), Microcrystalline cellulose (Avicel PH 102), Silica (Aerosil 200) and 
sodium starch glycolate, without addition of any non-volatile liquid vehicles. The 
composition of the formulation was given in Table 10C. 
7. PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
Powder flow is a critical character that might affect uniformity of the tablet 
weight. Therefore, the flow properties of the powder blend of all liquisolid 
formulations were determined in order to calculate that the amount of carrier and 
coating materials were required to maintain acceptable flow and compaction 
properties. The powder blend of all formulations was evaluated for precompression 
parameters such as angle of repose, bulk density, true density, carr’s index, Hausner’s 
ratio and drug content. 
a) Angle of Repose   
The angle of repose is a characteristic of the internal friction or cohesion of 
the particles, the value will be low, if the powder is non-cohesive and high if the 
powder is cohesive.  All the prepared formulations were in the ranges from 24.70o to 
29.39o, which indicates the good flow properties of liquisolid powder. The results of 
angle of repose of all formulations were shown in Table 11 and Figure 9a. 
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b) Bulk density 
Bulk density was used to measure the flow properties of the powder. The bulk 
density of the powder blend was in the range of 0.206 gm/ml to 0.825 gm/ml. The 
results of bulk density for all the formulations were shown in Table 11 and Figure 
9b. 
c) Tapped density 
The tapped density of the powder blend was in the range of 0.250 gm/ml to 
0.967 gm/ml. The results of bulk density for all the formulations were shown in Table 
11 and Figure  9c. 
d) Carr’s Index (CI) 
Determination of carr’s index, the ratio of bulk and tapped density, was used 
to measure the flow property of all liquisolid formulations. The decrease the value of 
the CI% would indicate the better flow properties of the powder.  The carr’s index of 
the all formulations was found to be in range of 6.41% to 19.99%. It was less than 
25%, which indicates that the powder blend have required flow property for 
compression of tablets. The results of carr’s index of all formulations were shown in 
Table 11 and Figure 9d. 
e) Hausner’s Ratio 
The Hausner’s ratio of all the formulations was found to be in range of 1.06 to 
1.24, which indicates better flow property of the powder blend. The results were 
shown in Table 11 and Figure 9e. 
f) Drug content 
The percentage drug content for all formulations was found to be in the range 
of 97.90% to 99.64%, ensured the uniformity of the drug content. The results 
 
CHAPTER IX                                                               RESULTS AND DISCUSSION 
 
Liquisolid tablets of Paliperidone Reg. No. 261211302 Page 85 
 
indicated all the formulations were within the limits as per IP (Limit: not less than 
85% and not more than 115%). The results were shown in Table 12 and Figure 9f.   
All the above precompressional evaluations were done for directly 
compressed tablets and they were within the limit (Table 15A).  
8. POSTCOMPRESSIONAL EVALUATION OF LIQUISOLID TABLETS 
Tablets of different formulations were evaluated for the postcompressional 
parameters such as general appearance, weight variation, hardness, thickness, 
friability, disintegration time and drug content for tablets. 
a) General appearance 
The formulated tablets were white in colour, biconvex and round shape. All 
the tablets were elegant in appearance. The results were shown in the Table 13. 
b) Thickness 
  The thickness of all the tablet formulations was used to determine the 
uniformity of size and shape of the tablets. All the prepared tablet formulations were 
measured by vernier caliper and were found to be in the range of 2.45 to 5.2mm. The 
results indicated that all the formulations had uniform size and shape. The results 
were shown in Table 13. 
c) Hardness 
             Hardness of tablet was used to determine the resistance to withstand 
mechanical shakes of handling in manufacture and packing. All the prepared tablets 
were determined using Monsanto hardness tester. The hardness of all the 
formulations was found to be 4 to 5 Kg/cm2, which indicates that all the tablet 
formulations had good mechanical strength. The results of all the formulations were 
shown in Table 13. 
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d) Weight variation 
The weight variation was used to ensure the uniformity of the tablet in all 
formulations. All the formulated tablets passes the weight variations within the 
acceptable limits as per IP. The results were shown in the Table 13. 
e)  Friability test 
            The friability of tablets was determined using Roche friabilator and used to 
determine the mechanical strength of tablets. The percentage friability of all the tablet 
formulations was found to be in the range of 0.10 to 0.77 %. It was less than 1%; the 
results indicated that all the tablet formulation had a good mechanical resistance of 
tablets. The results were shown in Table 13. 
f) Drug content 
          The drug content was used to determine the uniform amount of active 
ingredients present in all the formulations. The drug content was found to be in the 
range of 99.18% to 99.99%, which indicates all the formulations were within the 
acceptable limits as per IP (Limit: not less than 85% and not more than 115%). The 
results were shown in Table 14. 
g) Disintegration test 
  The disintegration time of all the tablet formulations was determined using 
Disintegration test apparatus.  All the prepared tablet formulations were in between 3 
min 30 sec to 8 min 7 sec. It was lesser than 15 min, which indicates all the 
formulations were within the acceptable limits as per IP. The results were shown in 
Table 13. 
All the above postcompressional evaluations were done for directly 
compressed tablets and they were within the limit (Table 15B). 
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9. INVITRO RELEASE STUDIES 
In vitro dissolution studies were carried out by USP type II method by using 
distilled water as a medium. The studies were performed in all the formulations for 1 
hour. The samples were taken at 5min interval for first 30 minutes, 15mins interval 
for next 30 minutes and absorbance was measured in UV spectrophotometer at 
237nm. 
Two formulation parameters such as effect of drug concentration in the liquid 
medication (ratio of drug and liquid vehicle) and effect of carrier/coating ratio (R-
value) that would affect the drug dissolution rate in immediate release liquisolid 
tablets were investigated. 
The results of in vitro release studies from liquisolid formulations shown in 
Table 16A to 16D and Figure: 10a to 10e. 
 Formulations F1, F3, F5, F7, F9, F11, F13, F15, F17 and F19 were prepared 
with 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 and 1:10 (ratio of drug and Tween 80) 
and 20:1 (ratio of MCC & Aerosil 200) showed the cumulative % of drug release 
64.11%, 68.03%, 73.20%, 76.50%, 80.43%, 83.09%, 88.52%, 93.08%, 95.48%, and 
94.24% respectively at the end of 1 hour.  Among the ten formulations F17 showed 
maximum release of 95.48%. The orders of percentage drug release were  
F1<F3< F5<F7<F9<F11<F13<F15<F19<F17 
Formulations F2, F4, F6, F8, F10, F12, F14, F16, F18 and F20 were prepared 
with 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 and 1:10 (ratio of drug and Tween 80) 
and 30:1 (ratio of MCC & Aerosil 200) showed the cumulative % of drug release 
65.24%, 70.63%, 74.75%, 79.13%, 84.95%, 85.71%, 90.28%, 96.79%, 98.10% and 
99.24% respectively at the end of 1 hour. Among the ten formulations F20 showed 
maximum release of 99.24%. The orders of percentage drug release were 
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F2<F4< F6<F8<F10<F12<F14<F16<F18<F20 
The formulations prepared with higher ratio of drug: liquid vehicle (1:10) 
have higher dissolution than smaller ratio of drug: liquid vehicle (1:1) in liquisolid 
formulations. 
From the above results, it was observed that the drug release was faster for 
formulation F20, containing the ratio 1:10 (drug:Tween 80) due to increase the 
amount of liquid vehicles. The enhanced drug dissolution rate may be mainly 
attributed to the fact that this poorly water-soluble drug is already in solution in 
Tween 80, while at the same time, it is carried by the powder particles 
(microcrystalline cellulose-silica) of liquid vehicle. Thus, its release is accelerated 
due to its markedly increased wettability and surface availability to the dissolution 
medium. 
Microcrystalline cellulose and Aerosil 200 were used as carrier and coating 
materials, respectively in prepared formulations. The effect of carrier and coating 
material ratio (R-value) on the drug dissolution were investigated. Two R-value of 20 
and 30 were studied. Generally, the higher R-value showed higher drug dissolution 
than the lower R-value.  
It was observed that formulation F20 with higher R-value showed a higher 
drug release than the formulation with lower R-value. Liquisolid tablets with high R-
value would contain high amount of microcrystalline cellulose (act as disintegrant), 
low amount of Aerosil 200 (hydrophobic in nature that would retard drug release) and 
low liquid load factor. 
The overall results indicated that the prepared immediate release liquisolid 
tablet formulation (F20) at the ratio of 1:10 (drug: Tween 80) and the higher R-value 
(30) which improved the dissolution behavior of drug (Nokhodchi. A et al., 2005). 
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Among all the 20 formulations, F20 was selected as a best formulation which 
had the better drug release rate (99.24% at 1hour). Accordingly, this improved drug 
release may result in a higher drug absorption in the gastrointestinal tract and thus, an 
improved oral bioavailability. 
10. POWDER X-RAY DIFFRACTION STUDIES 
Polymorphic changes in the drug are important factor which might affect the 
dissolution rate of drug and in turn bioavailability.  So that it is necessary to study the 
polymorphic changes of pure drug in liquisolid systems. The crystalline nature of 
drug was studied by the characteristic PXRD pattern which showed sharp peaks at 
14.81°, 21.40°, 22.00°, 23.17°, 24.80° and 26.40° at 2θ. PXRD for pure drug, 
excipients and liquisolid systems were showed in Figure 11a to 11d. 
Avicel PH 102 has a sharp characteristic peak at 22.78 at 2θ while liquisolid 
formulation powder obtained only one sharp characteristic peak at 23.00 at 2θ, which 
is evidence that Avicel PH 102 maintained its crystalline state. Liquisolid powder x-
ray diffraction pattern showed absence of these characteristic peaks of drug, which 
indicated pure drug, was entirely converted into amorphous or solubilized from. The 
absence of crystalinity in the liquisolid formulation might be due to solubilization of 
drug in liquid vehicle that is possibly absorbed and adsorbed on the carrier and 
coating material. The amorphization or solubilization of pure drug may result in an 
enhancement of dissolution rate (Sanjeev Ragavendra Gubbi et al., 2010 and Abdul 
Hasan Sathali A. and Deepa C. et al., 2013). 
11. ASSESSMENT AND COMPARISON OF DRUG DISSOLUTION RATES 
 The concentration of drug and Tween 80 is one of the main factors for the 
formulation of a liquisolid tablets and has considerable effect on the 10 min 
dissolution rate. Dissolution rate increased with an increase in the concentration of 
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Tween 80 due to high molecular dispersion states of the drug in the formulations. The 
results were shown in Table 17. The comparison of dissolution rate for pure drug, 
directly compressed tablets and liquisolid formulation were shown in Table 18 and                  
Figure 12. 
Formulations F1, F3, F5, F7, F9, F11, F13, F15, F17 and F19 were prepared 
with 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 and 1:10 (ratio of drug and Tween 80) 
and R-value of 20 showed the dissolution rate of 80.70 µg/min, 103.49 µg/min, 
125.00 µg/min, 150.32 µg/min, 176.90 µg/min, 198.42 µg/min, 216.14 µg/min, 
232.60 µg/min, 252.85 µg/min and 255.38 µg/min respectively at 10 min. Among the 
ten formulations F19 showed maximum dissolution rate of 255.38 µg/min. 
Formulations F2, F4, F6, F8, F10, F12, F14, F16, F18 and F20 were prepared 
with 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 and 1:10 (ratio of drug and Tween 80) 
and R-value of 30 showed the dissolution rate of 100.95 µg/min, 119.94 µg/min, 
135.13 µg/min, 156.65 µg/min, 188.29 µg/min, 206.02 µg/min, 231.33 µg/min, 
256.56 µg/min, 268.04 µg/min and 281.96 µg/min respectively at 10 min. Among the 
ten formulations F20 showed maximum dissolution rate of 281.96 µg/min.  
From the above results, it was observed that the dissolution rate was higher for 
formulation F20, containing the ratio 1:10 (drug:Tween 80). 
The dissolution rate of pure drug, directly compressed tablet and liquisolid 
formulation were showed 33.87 µg/min, 71.84µg/min and 281.96 µg/min 
respectively. As it clear from the figure 12, the liquisolid tablets displayed higher 
dissolution rate than those of directly compressed tablet and pure drug. 
According to the classic dissolution equation: 
DR = (D/h) S (CS – C) 
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The drug dissolution rate (DR) of a drug is directly proportional to its concentration 
gradient (Cs–C) in the stagnant diffusion layer and its surface (S) available for 
dissolution. Cs is the saturation solubility of the drug in the dissolution medium and, 
thus, it is a constant characteristic property related to the drug and dissolving liquid 
involved. Since all of dissolution tests for formulations were done at a constant 
rotational paddle speed (50 rpm) and identical dissolving media, we can assume that 
the thickness (h) of the stagnant diffusion layer and the diffusion coefficient (D) of 
the drug molecules remain almost identical. Therefore, the observed higher 
dissolution rates of paliperidone from liquisolid tablets are due to the significantly 
increased surface of the molecularly dispersed paliperidone. 
In addition, the saturation solubility of the drug in the microenvironment (Cs) 
might be increased in the liquisolid systems due to the presence of Tween 80. So, 
such an increase in Cs, in a larger drug concentration gradient, increases the 
dissolution rate of paliperidone according to the Noyes Whitney equation (Dinesh M. 
Pardhi et al., 2010 & Nokhodchi A. et al., 2005). 
12. SELECTION AND EVALUATION OF BEST FORMULATION 
From the above results of characterization F20 was selected as the best formulation. 
1. Solubility of drug in Tween 80 – 14.252 (mg/10ml) 
2. In vitro release studies              - 99.24% at 60 min 
1. Comparison of dissolution studies of best formulation with pure drug and 
directly compressed tablets 
The in vitro dissolution studies of best formulation (F20) were compared with 
pure drug and directly compressed tablets. The cumulative percentage of drug in 
formulation was found to be 99.24% in 1 hour compared to the pure drug and directly 
compressed tablets whose cumulative percentage drug release was found to be 
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16.50% & 35.20% in 1 hour, respectively. Thus the formulation F20 showed higher 
drug release than the pure drug and directly compressed tablets. The results were 
shown in Table 19 and Figure 13. 
2. Infrared spectroscopic studies 
Infrared spectrum was performed for the liquisolid formulation, the major 
peaks of the drug still shown in the spectrum at 3343.71 cm-1, 2902 cm-1, 1633.76 cm-
1, 1537.32 cm-1, 1429.30 cm-1, 1337.68 cm-1, 1281.74 cm-1, 1112.96 cm-1, 1031.95 
cm-1, 898.86 cm-1 indicated that there was no interaction between the drug and 
polymers in the preparation of liquisolid compacts. The result was shown in Figure 
7f. 
3. Differential scanning colorimetric studies 
The DSC thermogram of pure drug, excipients and final formulation were 
shown in Figure 8a to 8d. Pure paliperidone showed a sharp endothermic peak at 
187˚C corresponding to its melting temperature. Such sharp endothermic peak 
signifies that paliperidone used was in pure crystalline state. Microcrystalline 
cellulose showed sharp endothermic peak at 100.50 ˚C. The thermal behavior of 
aerosil 200 did not show any sharp endothermic peak and hence, the aerosil 200 was 
in an almost amorphous state. The sharp endothermic peak of pure drug was not 
observed in final formulation, which indicates that the paliperidone was molecularly 
dispersed and in an amorphous form (Sanjeev Gubbi et al., 2009 and Abdul Hasan 
Sathali A. and Deepa C. et al., 2013). 
4. Scanning electron microscopy analysis 
The surface morphology of liquisolid tablets was scanned using scanning 
electron microscopy. The result was shown in Figure 14. 
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The photomicrographs of the liquisolid system signify the complete 
disappearance of paliperidone crystals. It indicates that the drug was completely 
solubilized in liquisolid system and also indicates that even though the drug is in solid 
dosage form, it is held within the powder substrate in solution, almost  molecularly 
dispersed state, which contributes to enhanced dissolution rate of drug (Karmarkar 
A.B et al ., 2009). 
5. Stability studies              
The stability studies were investigated whether the physical chemical 
parameters and dissolution of liquisolid tablets is affected by storage under a             
40° C ± 2°C and  75%± 5% RH.  The best formulation of three batches is stored at 
40° C ± 2°C and  75%± 5% RH for two months.  The results showed no significant 
changes in physical appearance, hardness, thickness, drug content and dissolution test 
of aged tablets compared to the fresh liquisolid tablets.  This indicates that the 
liquisolid tablets were stable under these storage conditions. The results were shown 
in Table 20A & 20B & Figure 15. 
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TABLE 8: CALIBRATION OF PALIPERIDONE IN DISTILLED WATER 
 
 
S.NO 
 
CONCENTRATION 
(µg/ml) 
 
ABSORBANCE ± SD* 
 
1. 
 
1 
 
0.030 ± 0.001 
 
2. 
 
2 
 
0.060 ± 0.002 
 
3. 
 
3 
 
0.085 ± 0.001 
 
4. 
 
4 
 
0.113 ± 0.002 
 
5. 
 
5 
 
0.140 ± 0.002 
 
6. 
 
6 
 
0.171 ± 0.002 
 
7. 
 
7 
 
0.198 ± 0.001 
 
8. 
 
8 
 
0.228 ± 0.002 
 
9. 
 
9 
 
0.258 ± 0.001 
 
10. 
 
10 
 
0.286 ± 0.002 
           n=3*                                                                            γ = 0.9998 
 
 
 
 
 
 
 
  
 
 
TABLE 9: DETERMINATION OF SOLUBILITY OF PALIPERIDONE USING 
DIFFERENT NON-VOLATILE LIQUID VEHICLES 
 
 
S.NO 
 
NON-VOLATILE LIQUID 
VEHICLES 
 
SOLUBILITY (mg/10 ml) ± SD* 
 
 
1. 
 
PROPYLENE GLYCOL 
 
9.503 ± 0.10 
 
2. 
 
PEG 400 
 
8.331 ± 0.19 
 
3. 
 
TWEEN 80 14.252 ± 0.17 
 
4. 
 
CAPRYOL 90 
 
8.770 ± 0.10 
 
5. 
 
DISTILLED WATER 1.208 ± 0.09 
        n=6* 
 
 PEG 400 = Polyethylene Glycol 400, TWEEN 80= Polysorbate 80, CAPRYOL 90= 
Propylene Glycol Monocaprylate. 
 
 
 
TABLE 10A: COMPOSITION OF PALIPERIDONE LIQUISOLID TABLET 
 
Tween 80= Polysorbate 80, R = Carrier and coating material ratio, Lf =Liquid load factor, Q = W/Lf (Q= Carrier material and W=Total weight of drug and 
liquid vehicle), q=Q/R (q = Coating material), SSG= Sodium Starch Glycolate. 
Formulation 
code 
 
 
Non-volatile 
liquid 
vehicle 
Drug : 
liquid 
vehicle 
ratio 
R 
 
Active 
ingredient 
 
(mg) 
Liquid 
vehicle 
 
(mg) 
   Lf 
 
Avicel 
PH102 
Q  
(mg) 
Aerosil 
200 
q  
(mg) 
Disintegrant 
[SSG (5%)] 
 
(mg) 
Magnesium 
stearate 
[0.75%] 
(mg) 
Total 
weight of 
tablet 
(mg) 
F1 
 
Tween 80 
1:1 
 
20 6 6 0.200 59.85 2.99 3.74 0.58 79.17 
F2 
 
Tween 80 30 6 6 0.134 89.11 2.97 5.20 0.81 110.10 
F3 
 
Tween 80 
1:2 
 
20 6 12 0.200 89.78 4.49 5.61 0.88 118.76 
F4 
 
Tween 80 30 6 12 0.134 133.66 4.45 7.80 1.22 165.15 
F5 
 
Tween 80 
1:3 
 
20 6 18 0.200 119.70 5.98 7.48 1.17 158.34 
F6 
 
Tween 80 30 6 18 0.134 178.21 5.94 10.40 1.63 220.20 
F7 
 
Tween 80 
1:4 
 
20 6 24 0.200 149.62 7.48 9.35 1.47 197.93 
F8 
 
Tween 80 30 6 24 0.134 222.77 7.42 13.00 2.04 275.25 
F9 
 
Tween 80 
1:5 
 
20 6 30 0.200 179.55 8.97 11.22 1.76 237.52 
F10 
 
Tween 80 30 6 30 0.134 267.33 8.91 15.61 2.45 330.30 
TABLE 10B: COMPOSITION OF PALIPERIDONE LIQUISOLID TABLET 
 
Tween 80= Polysorbate 80, R = Carrier and coating material ratio, Lf =Liquid load factor, Q = W/Lf (Q= Carrier material and W=Total weight of drug and 
liquid vehicle), q=Q/R (q = Coating material), SSG= Sodium Starch Glycolate. 
Formulation 
code 
 
 
Non-volatile 
liquid 
vehicle 
Drug : 
liquid 
vehicle 
ratio 
R 
 
Active 
ingredient 
 
(mg) 
Liquid 
vehicle 
 
(mg) 
   Lf 
 
Avicel 
PH102 
Q  
(mg) 
Aerosil 
200 
q  
(mg) 
Disintegrant 
[SSG (5%)] 
 
(mg) 
Magnesium 
stearate 
[0.75%] 
(mg) 
Total 
weight of 
tablet 
(mg) 
F11 
 
Tween 80 
1:6 
 
20 6 36 0.200 209.48 10.47 13.09 2.06 277.11 
F12 
 
Tween 80 30 6 36 0.134 311.88 10.39 18.21 2.86 385.35 
F13 
 
Tween 80 
1:7 
 
20 6 42 0.200 239.40 11.97 14.96 2.35 316.69 
F14 
 
Tween 80 30 6 42 0.134 356.44 11.88 20.81 3.27 440.41 
F15 
 
Tween 80 
1:8 
 
20 6 48 0.200 269.33 13.46 16.83 2.65 356.28 
F16 
 
Tween 80 30 6 48 0.134 400.99 13.36 23.41 3.68 495.46 
F17 
 
Tween 80 
1:9 
 
20 6 54 0.200 299.25 14.96 18.71 2.94 395.87 
F18 
 
Tween 80 30 6 54 0.134 445.54 14.85 26.01 4.09 550.51 
F19 
 
Tween 80 
1:10 
 
20 6 60 0.200 329.18 16.45 20.58 3.24 435.45 
F20 
 
Tween 80 30 6 60 0.134 490.09 16.33 28.62 4.50 605.56 
  
 
 
 
 
 
TABLE 10C: COMPOSITION OF DIRECTLY COMPRESSED TABLETS 
S. No Ingredients 
Quantity for one 
tablet (mg) 
1. Paliperidone 6 
2. Avicel PH102 490.09 
3. Aerosil 200 16.33 
4. Sodium starch glycolate 25.62 
5. Magnesium stearate 4.03 
                                                                                         Total Weight = 542.07mg 
 
 
 
 
 
 
 
 
 
 
 
 TABLE 11: PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
 n= 3* 
 
 
 
Formulation 
code 
 
Angle of 
repose 
θ ± SD* 
 
Bulk 
density 
(g/ml) ± 
SD* 
Tapped 
density 
(g/ml) ± 
SD* 
Carr’s 
index 
(%) ± SD* 
 
Hausner’s 
ratio 
± SD* 
 
F1 28.96±0.74 0.206±0.01 0.250±0.00 17.57±2.12 1.20±0.03 
F2 27.92±0.79 0.324±0.01 0.367±0.02 11.84±0.60 1.13±0.01 
F3 29.35±1.48 0.334±0.01 0.403±0.01 16.98±0.44 1.20±0.00 
F4 29.39±0.80 0.495±0.03 0.604±0.04 18.05±1.19 1.22±0.00 
F5 28.93±0.68 0.515±0.01 0.640±0.02 19.54±0.77 1.23±0.01 
F6 28.18±1.02 0.644±0.00 0.782±0.00 17.63±0.06 1.21±0.00 
F7 28.43±0.83 0.657±0.00 0.821±0.00 19.99±0.02 1.24±0.00 
F8 28.49±0.86 0.698±0.01 0.824±0.02 15.23±0.46 1.17±0.00 
F9 29.00±0.59 0.737±0.00 0.910±0.00 18.75±0.05 1.22±0.00 
F10 28.19±0.60 0.763±0.05 0.886±0.07 13.88±1.00 1.15±0.01 
F11 26.81±1.13 0.798±0.02 0.967±0.03 17.34±0.59 1.20±0.00 
F12 27.55±0.29 0.780±0.03 0.888±0.04 12.16±0.55 1.13±0.00 
F13 27.42±0.65 0.807±0.06 0.899±0.07 10.21±0.81 1.10±0.01 
F14 24.70±0.92 0.759±0.02 0.827±0.04 8.08±2.23 1.08±0.02 
F15 27.02±0.52 0.721±0.01 0.847±0.00 14.82±2.00 1.17±0.02 
F16 25.30±1.17 0.791±0.03 0.845±0.04 6.41±0.27 1.06±0.00 
F17 27.05±0.66 0.771±0.04 0.874±0.05 11.77±0.70 1.13±0.01 
F18 25.45±0.65 0.801±0.02 0.878±0.03 8.75±0.26 1.09±0.00 
F19 26.81±1.24 0.805±0.02 0.906±0.03 11.12±0.43 1.12±0.01 
F20 25.00±0.25 0.825±0.03 0.916±0.00 9.96±1.44 1.11±0.01 
TABLE 12: DRUG CONTENT OF PALIPERIDONE POWDER BLEND 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
 
 
                       
                 n= 3* 
 
 
 
S.NO 
 
 
FORMULATION 
CODE 
 
DRUG CONTENT 
(%) ± SD* 
 
 
 1 F1 98.25±0.35 
 
2 F2 97.90±0.35 
 
3 F3 98.13±0.80 
 
4 F4 98.95±0.35 
 
5 F5 99.64±0.69 
 
6 F6 99.18±0.53 
 
7 F7 99.18±0.20 
 
8 F8 99.30±0.60 
 
9 F9 99.06±0.20 
 
10 F10 99.30±0.35 
 
11 F11 99.30±0.70 
 
12 F12 99.06±0.20 
 
13 F13 99.06±0.40 
 
14 F14 98.83±0.88 
 
15 F15 99.41±0.20 
 
16 F16 98.95±0.35 
 
17 F17 99.30±0.35 
 
18 F18 99.06±1.11 
 
19 F19 99.53±0.20 
 
20 F20 99.64±0.69 
  
TABLE 13: POST COMPRESSIONAL EVALUATION OF LIQUISOLID 
TABLETS 
n=3* 
 
 
 
 
Formulation 
code 
 
General 
appearance 
 
Hardness
(kg/cm2) 
 
Thickness
(mm) 
 
Weight 
variation(mg) 
 
Friability 
(%) 
 
Disintegration 
Time(sec) 
 
F1 White colour 4 2.52 76.1 - 79.4 0.44 8 min 7 sec 
F2 White colour 4 3.21 107.80 - 110.30 0.17 7 min 14 sec 
F3 White colour 4 3.48 116.8 - 118.5  0.21 6 min 45 sec 
F4 White colour 5 2.45 164.7 - 166 0.11 6 min 33 sec 
F5 White colour 5 2.58 157.4 - 159 0.4 6 min 42 sec 
F6 White colour 5 3.34 218.9 - 220.4 0.19 6 min 5 sec 
F7 White colour 5 2.94 196.5 - 197.3 0.68 6 min 24 sec 
F8 White colour 5 4.21 274.5 - 275.2 0.46 5 min 35 sec 
F9 White colour 5 3.7 236.2 - 237.5 0.68 6 min 1 sec 
F10 White colour 5 4.15 328.9 - 330.1 0.77 5 min 35 sec 
F11 White colour 5 4.23 276.3 - 277.2 0.48 5 min 26 sec 
F12 White colour 5 4.9 384.8 - 285.2 0.12 5 min 25 sec 
F13 White colour 5 3.86 315.8 - 316.5 0.4 5 min 23 sec 
F14 White colour 5 5.2 439.5 - 440.2 0.21 5 min 13 sec 
F15 White colour 5 4.15 355.2 - 356.2 0.25 5 min 17 sec 
F16 White colour 5 3.84 494.5 - 495.4 0.16 4 min 33 sec 
F17 White colour 5 4.75 394.8 - 395.7 0.17 5 min 11 sec 
F18 White colour 5 4.47 549.7 - 550.5 0.11 4 min 12 sec 
F19 White colour 5 4.95 435 - 435.7 0.1 4 min 36 sec 
F20 White colour 5 4.92 604.7 - 605.3 0.16 3 min 30 sec 
 TABLE 14: DRUG CONTENT OF PALIPERIDONE LIQUISOLID TABLET 
 
S NO 
 
 
FORMULATION 
CODE 
 
DRUG CONTENT (%) 
± SD*  
 
1 F1 99.53±0.20 
2 F2 99.76±0.52 
3 F3 99.76±0.52 
4 F4 99.88±0.39 
5 F5 99.99±0.34 
6 F6 99.88±0.39 
7 F7 99.88±0.53 
8 F8 99.53±0.20 
9 F9 99.41±0.20 
10 F10 99.65±0.35 
11 F11 99.64±0.60 
12 F12 99.30±0.35 
13 F13 99.41±0.53 
14 F14 99.64±0.69 
15 F15 99.41±0.20 
16 F16 99.30±0.35 
17 F17 99.18±0.20 
18 F18 99.53±0.72 
19 F19 99.18±0.20 
20 F20 99.41±0.40 
          n=3* 
 
 
TABLE 15A: PRECOMPRESSIONAL EVALUATION FOR DIRECTLY  
COMPRESSED TABLETS 
 
 
S.NO 
 
PARAMETERS 
 
VALUES 
 
1. 
 
Angle of repose ± SD 
 
24.01 ± 0.21 
 
2. 
 
Bulk density ± SD 
 
0.624 ± 0.02 
 
3. 
 
Tapped density ± SD 
 
0.683 ± 0.03 
 
4. 
 
Carr’s index ± SD 
 
8.67 ± 0.33 
 
5. 
 
Hausner’s ratio ± SD 
 
1.09 ± 0.00 
 
6. 
 
Drug content ± SD 
 
98.95% ± 0.35 
 
TABLE 15B: POST COMPRESSIONAL EVALUATION FOR DIRECTLY  
COMPRESSED TABLETS 
 
 
S.NO 
 
PARAMETERS 
 
VALUES 
 
1. 
 
Hardness 
 
5 kg/cm2 
 
2. 
 
Thickness 
 
4.38 mm 
 
3. 
 
Diameter 
 
12 mm 
 
4. 
 
Weight variation 
 
536.7 – 542.6 mg 
 
5. 
 
Friability 
 
0.23 % 
 
6. 
 
Drug content ± SD 
 
99.41% ± 0.20 
 
7. 
 
Disintegration time 
 
14 min 23 sec 
 
 
TABLE 16A: IN VITRO RELEASE PROFILE OF PALIPERIDONE 
LIQUISOLID FORMULATION 
TIME IN 
MINUTES 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ± SD* 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
5 8.55±0.63 10.03±0.36 10.87±0.36 12.35±0.63 12.98±0.63 
10 13.45±0.96 16.82±0.63 17.24±0.73 19.99±0.63 20.83±0.96 
15 22.17±0.96 23.03±0.36 23.88±0.63 24.32±0.36 26.22±0.96 
20 29.25±0.73 29.91±1.32 32.45±0.36 34.37±0.96 35.01±0.96 
25 33.42±1.32 37.46±0.62 38.75±1.67 41.94±0.63 42.17±0.72 
30 45.63±1.58 47.58±0.36 48.03±0.36 49.34±0.97 51.05±0.63 
45 54.11±1.59 57.12±0.37 59.26±0.72 63.33±0.64 64.41±1.32 
60 64.11±0.62 65.24±0.97 68.03±0.63 70.63±0.64 73.20±0.63 
n=3* 
 
TABLE 16B: IN VITRO RELEASE PROFILE OF PALIPERIDONE 
LIQUISOLID FORMULATION 
TIME IN 
MINUTES 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ± SD* 
 
F6 
 
F7 
 
F8 
 
F9 
 
F10 
 
5 15.73±0.36 16.78±0.63 18.05±0.63 19.95±0.63 21.63±0.73 
10 22.52±0.63 25.05±0.63 26.10±0.36 29.48±0.63 31.38±0.63 
15 27.71±0.63 29.20±0.73 33.42±1.26 32.81±0.62 36.19±0.96 
20 36.30±0.36 37.80±0.37 40.99±0.36 41.43±0.96 44.41±0.63 
25 45.36±0.36 47.92±0.97 50.29±0.63 51.36±0.36 53.94±0.97 
30 52.99±1.26 56.20±0.64 60.06±0.64 61.14±0.36 63.94±0.64 
45 67.42±0.36 68.74±0.35 71.99±0.98 72.23±0.37 75.68±1.28 
60 74.75±0.72 76.50±0.64 79.13±0.61 80.43±0.63 84.95±0.63 
n=3* 
 
TABLE 16C: IN VITRO RELEASE PROFILE OF PALIPERIDONE 
LIQUISOLID FORMULATION 
TIME IN 
MINUTES 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ± SD* 
 
F11 
 
F12 
 
F13 
 
F14 
 
F15 
 
5 22.48±0.63 23.74±0.63 23.95±0.96 25.01±0.63 26.91±0.63 
10 33.07±0.96 34.33±0.36 36.02±0.96 38.55±0.96 38.76±0.36 
15 37.26±0.63 38.53±0.63 39.81±0.63 42.56±0.36 45.94±0.96 
20 45.69±0.62 49.50±0.63 51.42±0.63 55.67±0.36 57.37±0.97 
25 54.59±0.36 57.37±0.62 61.41±0.97 64.20±0.36 66.34±1.27 
30 64.60±0.63 68.23±0.96 70.60±0.98 72.36±1.27 73.03±0.65 
45 76.55±0.36 79.16±0.36 80.90±0.64 80.98±0.63 82.93±1.28 
60 83.09±0.63 85.71±0.63 88.52±0.35 90.28±0.62 93.08±0.99 
n=3* 
 
TABLE 16D: IN VITRO RELEASE PROFILE OF PALIPERIDONE 
LIQUISOLID FORMULATION 
TIME IN 
MINUTES 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ± SD* 
 
F16 
 
F17 
 
F18 
 
F19 
 
F20 
 
5 31.97±0.63 30.70±1.26 34.08±0.36 32.39±0.36 38.93±0.63 
10 42.77±0.63 42.14±0.63 44.67±0.63 42.56±0.36 46.99±0.96 
15 49.97±0.63 48.28±0.36 49.98±0.63 48.49±0.36 54.42±0.63 
20 61.01±0.63 60.15±0.96 62.91±0.63 60.57±0.36 64.85±0.63 
25 69.15±0.97 67.23±0.37 69.80±0.36 68.29±0.63 72.59±0.97 
30 77.54±0.64 75.19±0.37 78.20±1.68 75.42±0.36 79.53±0.64 
45 86.83±0.64 84.89±0.64 88.97±1.33 87.01±0.97 91.99±1.28 
60 96.79±0.65 95.48±0.64 98.10±0.65 94.24±0.62 99.24±0.35 
n=3* 
 
TABLE 17: DISSOLUTION RATE OF DRUG AFTER 10 MIN 
 
S.NO 
 
FORMULATION 
CODE 
 
DISSOLUTION RATE 
AFTER 10 MIN 
(µg/min) 
 
1 
 
F1 
 
80.70 
 
2 
 
F2 
 
100.95 
 
3 
 
F3 
 
103.49 
 
4 
 
F4 
 
119.94 
 
5 
 
F5 
 
125.00 
 
6 
 
F6 
 
135.13 
 
7 
 
F7 
 
150.32 
 
8 
 
F8 
 
156.65 
 
9 
 
F9 
 
176.90 
 
10 
 
F10 
 
188.29 
 
11 
 
F11 
 
198.42 
 
12 
 
F12 
 
206.02 
 
13 
 
F13 
 
216.14 
 
14 
 
F14 
 
231.33 
 
15 
 
F15 
 
232.60 
 
16 
 
F16 
 
256.65 
 
17 
 
F17 
 
252.85 
 
18 
 
F18 
 
268.04 
 
19 
 
F19 
 
255.38 
 
20 
 
F20 
 
281.96 
 
 
  
 
 
 
 
 
TABLE 18: COMPARISON OF DISSOLUTION RATE OF PURE DRUG, 
CONVENTIONAL TABLET AND BEST FORMULATION AFTER 10 MIN 
 
 
DISSOLUTION RATE AFTER 10 MIN (µg/min) 
 
 
 
PURE DRUG 
 
 
33.87 
 
 
CONVENTIONAL TABLET 
 
 
71.84 
 
 
BEST FORMULATION 
 
 
281.96 
 
 
 
 
 
 
 
 
 
 
  
 
TABLE 19: COMPARISON OF IN VITRO RELEASE PROFILE FOR 
PURE DRUG, CONVENTIONAL TABLET AND LIQUISOLID TABLET 
 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ± SD* 
 
 
TIME IN 
MINUTES 
 
5 
 
10 
 
15 
 
20 
 
25 
 
30 
 
45 
 
60 
 
PURE DRUG 
 
4.33±0.36 
 
5.64±0.36 
 
6.94±0.36 
 
8.24±0.36 
 
10.40±0.36 
 
11.30±0.00 
 
13.89±0.62 
 
 
16.50±0.63 
 
 
CONVENTIONAL 
TABLET 
8.76±0.36 
 
11.97±0.36
 
15.41±0.36 
 
17.61±0.63 
 
21.50±0.63 
 
23.94±0.97 
 
29.34±0.64 
 
35.20±0.64 
 
 
LIQUISOLID 
TABLET 
 
 
38.93±0.63
 
 
46.99±0.96 54.42±0.63 
 
64.85±0.63 
 
72.59±0.97 
 
79.53±0.64 
 
91.99±1.28 
 
99.24±0.35 
 
  n=3* 
 
 
  
TABLE 20A: STABILITY STUDY OF BEST FORMULATION (F20) AT 
40° C ± 2°C AND 75%± 5% 
 
TABLE 20B: DISSOLUTION PROFILE OF BEST FORMULATION (F20) AT 
40° C ± 2°C AND 75%± 5% 
Time interval 
(min) 
 
Percentage of drug release 
AT 0 MONTH AT 1MONTH AT 2MONTH 
 
5 38.93±0.63 37.24±0.36 37.03±0.63 
 
10 46.99±0.96 45.30±1.67 45.09±1.82 
 
15 54.42±0.63 52.94±0.72 52.73±0.95 
 
20 64.85±0.63 63.36±1.32 63.35±1.32 
 
25 72.59±0.97 70.88±1.33 70.45±2.04 
 
30 79.53±0.64 78.88±1.33 78.43±1.33 
 
45 91.99±1.28 90.89±1.96 90.68±1.70 
 
60 
99.24±0.35 98.14±0.04 97.92±0.36 
 
 
PARAMETERS 
 
INTERVAL OF TESTING 
 
AT 0 MONTH 
 
AT 1MONTH 
 
AT 2MONTH 
 
Physical 
appearance 
White colour, 
biconvex shaped 
White colour, 
biconvex shaped 
White colour, 
biconvex shaped 
 
Hardness 
(kg/cm2) 
5 5 5 
 
Thickness (mm) 
 
4.92 4.92 4.92 
 
Drug content 
(%)±SD 
99.41±0.40 99.06±0.72 98.97±0.54 
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CHAPTER - X 
SUMMARY AND CONCLUSION 
 
 The purpose of the study was to formulate liquisolid tablets of Paliperidone to 
improve the solubility and dissolution rate.  
 The λmax of Paliperidone was found to be 237nm in distilled water. 
 The Paliperidone obeys Beer’s law within the concentration range of 1-10 
(µg/ml). 
    The solubility studies were observed that the Paliperidone have highest 
solubility in Tween 80 compared to other non-volatile liquid vehicles. 
    FT-IR showed that there was no interaction between the drug and excipients. 
 The DSC thermogram of Paliperidone and liquisolid compacts, the sharp 
endothermic peak of pure drug appeared at 187oC, whereas no such peak was 
observed in liquisolid formulation, which indicates that Paliperidone was 
molecularly dispersed and in an amorphous form. 
  Flowable liquid retention potential (Ф-value) was used to formulate 
liquisolid tablets of Paliperidone. 
 The twenty formulations were prepared using different concentration of drug 
in liquid medication, and different ratio of microcrystalline cellulose & 
aerosil 200 and sodium starch glycolate. 
 The directly compressed tablets were prepared using microcrystalline 
cellulose and aerosil 200 and sodium starch glycolate, without addition of 
non-volatile liquid vehicle. 
 The results of precompression studies which indicates that the prepared 
powder blend of all the formulations possess good flow properties. 
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 The postcompression evaluations such as hardness, thickness, weight 
variation, friability, drug content and disintegration test of all the formulated 
liquisolid tablets were within the acceptable limits. 
 In vitro dissolution studies of all the formulations showed immediate release 
of drug. Among 20 formulations F20 was selected as a best formulation 
which had the better release of drug (99.24%) and subjected to further 
studies. 
 The in vitro release studies revealed that the liquisolid tablets showed a faster 
drug release compared to the pure drug and directly compressed tablets. 
 The results of the powder X- ray diffraction studies proved that the 
crystallinity of pure drug was remarkably reduced in the best formulation. 
 The dissolution rate was increased, when the amount of non-volatile liquid 
increased from drug:Tween 80 ratio of 1:1 to 1:10. 
 The dissolution rate (DR) in 10 min, increased in linear manner with 
increasing ratio of drug: Tween 80. 
 The selected formulation showed higher release profile than the pure drug 
and directly compressed tablets. 
 The SEM image of the selected formulation showed complete disappearance 
of Paliperidone crystals. 
 The selected formulation was found to be stable under the storage condition. 
 
 
 
 
CHAPTER  X                                                         SUMMARY AND CONCLUSION 
 
Liquisolid tablets of Paliperidone Reg. No. 261211302 Page 96 
 
CONCLUSION 
The liquisolid tablet technique can be effective way for dissolution rate 
improvement of water insoluble drugs such as Paliperidone. Tween 80 was used as a 
liquid vehicle. The liquid vehicle plays a contributing role in improving the 
dissolution profiles of a water insoluble drug in the liquisolid formulations, besides 
choosing a suitable liquid vehicle according to its viscosity and HLB value. Enhanced 
dissolution rates obtained in the present study in turn indicates increase in oral 
bioavailability due to increased wetting and surface area available for dissolution. 
Hence we can conclude that liquisolid tablets of paliperidone was prepared by using 
Tween 80 (1:10 ratio of drug and Tween 80) and 30 ratio of microcrystalline cellulose 
and aerosil 200 provide greater release of drug (99.24 % in 60 mins) among all the 
formulations, and this ratio can be used to enhance the solubility and dissolution rate 
of poorly water soluble drug paliperidone. This novel approach to the formulation 
may be helpful to improve oral bioavailability. 
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